Precision Oncology, Signaling, and Anticancer Agents in Cancer Therapeutics

Dagogo-Jack, I.; Shaw, A.T. Tumour heterogeneity and resistance to cancer therapies.Nature Rev. Clin. Oncolo., 2018, 15.2, 81.,
[http://dx.doi.org/10.1038/nrclinonc.2017.166]

Falzone, L.; Salomone, S.; Libra, M. Evolution of cancer pharmacological treatments at the turn of the third millennium. Front. Pharmacol., 2018, 9(9), 1300.
[http://dx.doi.org/10.3389/fphar.2018.01300] [PMID: 30483135]

Seyhan, A.A.; Carini, C. Are innovation and new technologies in precision medicine paving a new era in patients centric care? J. Transl. Med., 2019, 17(1), 114.
[http://dx.doi.org/10.1186/s12967-019-1864-9] [PMID: 30953518]

Salgado, R.; Moore, H.; Martens, J.W.M.; Lively, T.; Malik, S.; McDermott, U.; Michiels, S.; Moscow, J.A.; Tejpar, S.; McKee, T.; Lacombe, D. Steps forward for cancer precision medicine. Nat. Rev. Drug Discov., 2018, 17(1), 1-2.
[http://dx.doi.org/10.1038/nrd.2017.218] [PMID: 29170471]

Xue, Y.; Wilcox, W.R. Changing paradigm of cancer therapy: precision medicine by next-generation sequencing. Cancer Biol. Med., 2016, 13(1), 12-18.
[http://dx.doi.org/10.20892/j.issn.2095-3941.2016.0003] [PMID: 27144059]

Homer, C. Human services. Public Health Rep., 2017, 132(2), 127-129.
[http://dx.doi.org/10.1177/0033354916689662] [PMID: 28135429]

Prasad, V.; Fojo, T.; Brada, M. Precision oncology: origins, optimism, and potential. Lancet Oncol., 2016, 17(2), e81-e86.
[http://dx.doi.org/10.1016/S1470-2045(15)00620-8] [PMID: 26868357]

Krzyszczyk, P.; Acevedo, A.; Davidoff, E.J.; Timmins, L.M.; Marrero-Berrios, I.; Patel, M.; White, C.; Lowe, C.; Sherba, J.J.; Hartmanshenn, C.; O’Neill, K.M.; Balter, M.L.; Fritz, Z.R.; Androulakis, I.P.; Schloss, R.S.; Yarmush, M.L. The Growing role of precision and personalized medicine for cancer treatment. Technology, 2018, 6(03n04), 79-100.,
[http://dx.doi.org/10.1142/S2339547818300020]

Bode, A.M.; Dong, Z. Recent advances in precision oncology research. NPJ Precis. Oncol., 2018, 2, 11.

Soldatos, T.G.; Kaduthanam, S.; Jackson, D.B. Precision oncology-the quest for evidence. J. Pers. Med., 2019, 9(3), 43.
[http://dx.doi.org/10.3390/jpm9030043] [PMID: 31492009]

Long, G.V.; Hauschild, A.; Santinami, M.; Atkinson, V.; Mandalà, M.; Chiarion-Sileni, V.; Larkin, J.; Nyakas, M.; Dutriaux, C.; Haydon, A.; Robert, C.; Mortier, L.; Schachter, J.; Schadendorf, D.; Lesimple, T.; Plummer, R.; Ji, R.; Zhang, P.; Mookerjee, B.; Legos, J.; Kefford, R.; Dummer, R.; Kirkwood, J.M. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N. Engl. J. Med., 2017, 377(19), 1813-1823.
[http://dx.doi.org/10.1056/NEJMoa1708539] [PMID: 28891408]

Mavaddat, N.; Pharoah, P.D.P.; Michailidou, K.; Tyrer, J.; Brook, M.N.; Bolla, M.K. Prediction of breast cancer risk based on profiling with common genetic variants. J. Natl. Cancer Inst., 2015, 107, 5.

Maas, P.; Barrdahl, M.; Joshi, A.D.; Auer, P.L.; Gaudet, M.M.; Milne, R.L.; Schumacher, F.R.; Anderson, W.F.; Check, D.; Chattopadhyay, S.; Baglietto, L.; Berg, C.D.; Chanock, S.J.; Cox, D.G.; Figueroa, J.D.; Gail, M.H.; Graubard, B.I.; Haiman, C.A.; Hankinson, S.E.; Hoover, R.N.; Isaacs, C.; Kolonel, L.N.; Le Marchand, L.; Lee, I.M.; Lindström, S.; Overvad, K.; Romieu, I.; Sanchez, M.J.; Southey, M.C.; Stram, D.O.; Tumino, R.; VanderWeele, T.J.; Willett, W.C.; Zhang, S.; Buring, J.E.; Canzian, F.; Gapstur, S.M.; Henderson, B.E.; Hunter, D.J.; Giles, G.G.; Prentice, R.L.; Ziegler, R.G.; Kraft, P.; Garcia-Closas, M.; Chatterjee, N. Breast cancer risk from modifiable and nonmodifiable risk factors among white women in the United States. JAMA Oncol., 2016, 2(10), 1295-1302.
[http://dx.doi.org/10.1001/jamaoncol.2016.1025] [PMID: 27228256]

Bristow, R.G.; Alexander, B.; Baumann, M.; Bratman, S.V.; Brown, J.M.; Camphausen, K.; Choyke, P.; Citrin, D.; Contessa, J.N.; Dicker, A.; Kirsch, D.G.; Krause, M.; Le, Q.T.; Milosevic, M.; Morris, Z.S.; Sarkaria, J.N.; Sondel, P.M.; Tran, P.T.; Wilson, G.D.; Willers, H.; Wong, R.K.S.; Harari, P.M. Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology. Lancet Oncol., 2018, 19(5), e240-e251.
[http://dx.doi.org/10.1016/S1470-2045(18)30096-2] [PMID: 29726389]

Paik, S.; Shak, S.; Tang, G.; Kim, C.; Baker, J.; Cronin, M.; Baehner, F.L.; Walker, M.G.; Watson, D.; Park, T.; Hiller, W.; Fisher, E.R.; Wickerham, D.L.; Bryant, J.; Wolmark, N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med., 2004, 351(27), 2817-2826.
[http://dx.doi.org/10.1056/NEJMoa041588] [PMID: 15591335]

Mamounas, E.P.; Tang, G.; Fisher, B.; Paik, S.; Shak, S.; Costantino, J.P.; Watson, D.; Geyer, C.E., Jr; Wickerham, D.L.; Wolmark, N. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J. Clin. Oncol., 2010, 28(10), 1677-1683.
[http://dx.doi.org/10.1200/JCO.2009.23.7610] [PMID: 20065188]

Northcott, P.A.; Korshunov, A.; Witt, H.; Hielscher, T.; Eberhart, C.G.; Mack, S.; Bouffet, E.; Clifford, S.C.; Hawkins, C.E.; French, P.; Rutka, J.T.; Pfister, S.; Taylor, M.D. Medulloblastoma comprises four distinct molecular variants. J. Clin. Oncol., 2011, 29(11), 1408-1414.
[http://dx.doi.org/10.1200/JCO.2009.27.4324] [PMID: 20823417]

Kamran, S.C.; Mouw, K.W. Applying precision oncology principles in radiation oncology. JCO Precis Oncol, 2018, 2, 1-23.
[http://dx.doi.org/10.1200/PO.18.00034] [PMID: 32914000]

Lohaus, F.; Linge, A.; Tinhofer, I.; Budach, V.; Gkika, E.; Stuschke, M.; Balermpas, P.; Rödel, C.; Avlar, M.; Grosu, A.L.; Abdollahi, A.; Debus, J.; Bayer, C.; Belka, C.; Pigorsch, S.; Combs, S.E.; Mönnich, D.; Zips, D.; von Neubeck, C.; Baretton, G.B.; Löck, S.; Thames, H.D.; Krause, M.; Baumann, M. HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiother. Oncol., 2014, 113(3), 317-323.
[http://dx.doi.org/10.1016/j.radonc.2014.11.011] [PMID: 25480095]

Fatehullah, A.; Tan, S.H.; Barker, N. Organoids as an in vitro model of human development and disease. Nat. Cell Biol., 2016, 18(3), 246-254.
[http://dx.doi.org/10.1038/ncb3312] [PMID: 26911908]

Liu, X.; Krawczyk, E.; Suprynowicz, F.A.; Palechor-Ceron, N.; Yuan, H.; Dakic, A.; Simic, V.; Zheng, Y.L.; Sripadhan, P.; Chen, C.; Lu, J.; Hou, T.W.; Choudhury, S.; Kallakury, B.; Tang, D.G.; Darling, T.; Thangapazham, R.; Timofeeva, O.; Dritschilo, A.; Randell, S.H.; Albanese, C.; Agarwal, S.; Schlegel, R. Conditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens. Nat. Protoc., 2017, 12(2), 439-451.
[http://dx.doi.org/10.1038/nprot.2016.174] [PMID: 28125105]

Vaira, V.; Fedele, G.; Pyne, S.; Fasoli, E.; Zadra, G.; Bailey, D.; Snyder, E.; Faversani, A.; Coggi, G.; Flavin, R.; Bosari, S.; Loda, M. Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc. Natl. Acad. Sci. USA, 2010, 107(18), 8352-8356.
[http://dx.doi.org/10.1073/pnas.0907676107] [PMID: 20404174]

Zhang, B.; Korolj, A.; Lai, B.F.L.; Radisic, M. Advances in organ-on-a-chip engineering. Nat. Rev. Mater., 2018, 3(8), 257-278.
[http://dx.doi.org/10.1038/s41578-018-0034-7]

Bregenzer, M.E.; Horst, E.N.; Mehta, P.; Novak, C.M.; Raghavan, S.; Snyder, C.S.; Mehta, G. Integrated cancer tissue engineering models for precision medicine. PLoS One, 2019, 14(5)e0216564
[http://dx.doi.org/10.1371/journal.pone.0216564] [PMID: 31075118]

Skardal, A.; Devarasetty, M.; Forsythe, S.; Atala, A.; Soker, S. A reductionist metastasis-on-a-chip platform for in vitro tumor progression modeling and drug screening. Biotechnol. Bioeng., 2016, 113(9), 2020-2032.
[http://dx.doi.org/10.1002/bit.25950] [PMID: 26888480]

Sobrino, A.; Phan, D.T.T.; Datta, R.; Wang, X.; Hachey, S.J.; Romero-López, M.; Gratton, E.; Lee, A.P.; George, S.C.; Hughes, C.C. 3D microtumors in vitro supported by perfused vascular networks. Sci. Rep., 2016, 6(1), 31589.
[http://dx.doi.org/10.1038/srep31589] [PMID: 27549930]

Saad, E.D.; Paoletti, X.; Burzykowski, T.; Buyse, M. Precision medicine needs randomized clinical trials. Nat. Rev. Clin. Oncol., 2017, 14(5), 317-323.
[http://dx.doi.org/10.1038/nrclinonc.2017.8] [PMID: 28169302]

Bourin, M. Phase III Clinical trials: what methodology? SOJ Pharm. Pharm. Sci., 2017, 16(1), 122.

Buyse, M.; Sargent, D.J.; Grothey, A.; Matheson, A.; de Gramont, A. Biomarkers and surrogate end points-the challenge of statistical validation. Nat. Rev. Clin. Oncol., 2010, 7(6), 309-317.
[http://dx.doi.org/10.1038/nrclinonc.2010.43] [PMID: 20368727]

Hu, F.; Hu, Y.; Ma, W.; Zhang, L.; Zhu, H. Statistical inference of adaptive randomized clinical trials for personalized medicine. Clin. Investig. (Lond.), 2015, 5(4), 415-425.
[http://dx.doi.org/10.4155/cli.15.15]

Shen, D. Paper PO06 Randomization in Clinical Trial Studies. Trial, 2006.

Lim, C.Y.; In, J. Randomization in clinical studies. Korean J. Anesthesiol., 2019, 72(3), 221-232.
[http://dx.doi.org/10.4097/kja.19049] [PMID: 30929415]

Harrington, J.A.; Hernandez-Guerrero, T.C.; Basu, B. Early phase clinical trial designs-state of play and adapting for the future. Clin. Oncol. (R. Coll. Radiol.), 2017, 29(12), 770-777.
[http://dx.doi.org/10.1016/j.clon.2017.10.005] [PMID: 29108786]

Garralda, E.; Dienstmann, R.; Piris-Giménez, A.; Braña, I.; Rodon, J.; Tabernero, J. New clinical trial designs in the era of precision medicine. Mol. Oncol., 2019, 13(3), 549-557.
[http://dx.doi.org/10.1002/1878-0261.12465] [PMID: 30698321]

Pemovska, T.; Kontro, M.; Yadav, B.; Edgren, H.; Eldfors, S.; Szwajda, A.; Almusa, H.; Bespalov, M.M.; Ellonen, P.; Elonen, E.; Gjertsen, B.T.; Karjalainen, R.; Kulesskiy, E.; Lagström, S.; Lehto, A.; Lepistö, M.; Lundán, T.; Majumder, M.M.; Marti, J.M.; Mattila, P.; Murumägi, A.; Mustjoki, S.; Palva, A.; Parsons, A.; Pirttinen, T.; Rämet, M.E.; Suvela, M.; Turunen, L.; Västrik, I.; Wolf, M.; Knowles, J.; Aittokallio, T.; Heckman, C.A.; Porkka, K.; Kallioniemi, O.; Wennerberg, K. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov., 2013, 3(12), 1416-1429.
[http://dx.doi.org/10.1158/2159-8290.CD-13-0350] [PMID: 24056683]

Park, J.J.H.; Siden, E.; Zoratti, M.J.; Dron, L.; Harari, O.; Singer, J. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. Trials, 2019, 20(1), 1-10.
[http://dx.doi.org/10.1186/s13063-019-3664-1]

Renfro, L.A.; Sargent, D.J. Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. Ann. Oncol., 2017, 28(1), 34-43.
[http://dx.doi.org/10.1093/annonc/mdw413] [PMID: 28177494]

Ferrarotto, R.; Redman, M.W.; Gandara, D.R.; Herbst, R.S.; Papadimitrakopoulou, V.A. Lung-MAP--framework, overview, and design principles. Linchuang Zhongliuxue Zazhi, 2015, 4(3), 36-36.
[PMID: 26408303]

Govindan, R.; Mandrekar, S.J.; Gerber, D.E.; Oxnard, G.R.; Dahlberg, S.E.; Chaft, J.; Malik, S.; Mooney, M.; Abrams, J.S.; Jänne, P.A.; Gandara, D.R.; Ramalingam, S.S.; Vokes, E.E. Alchemist trials: a golden opportunity to transform outcomes in early-stage non-small cell lung cancer. Clin. Cancer Res., 2015, 21(24), 5439-5444.
[http://dx.doi.org/10.1158/1078-0432.CCR-15-0354] [PMID: 26672084]

Li, B.T.; Shen, R.; Buonocore, D.; Olah, Z.T.; Ni, A.; Ginsberg, M.S.; Ulaner, G.A.; Offin, M.; Feldman, D.; Hembrough, T.; Cecchi, F.; Schwartz, S.; Pavlakis, N.; Clarke, S.; Won, H.H.; Brzostowski, E.B.; Riely, G.J.; Solit, D.B.; Hyman, D.M.; Drilon, A.; Rudin, C.M.; Berger, M.F.; Baselga, J.; Scaltriti, M.; Arcila, M.E.; Kris, M.G. Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial. J. Clin. Oncol., 2018, 36(24), 2532-2537.
[http://dx.doi.org/10.1200/JCO.2018.77.9777] [PMID: 29989854]

Li, B.T.; Makker, V.; Buonocore, D.J.; Offin, M.D.; Olah, Z.T.; Panora, E. A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers. J. Clin. Oncol., 2018, 36(15), 2502-2502.
[http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.2502]

Diaz, L.; Marabelle, A.; Kim, T.W.; Geva, R.; Van Cutsem, E.; André, T. Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers. Ann. Oncol., 2017, 28(suppl_5).,

Diaz, L.A.; Le, D.; Maio, M.; Ascierto, P.A.; Geva, R.; Motola-Kuba, D. Pembrolizumab in microsatellite instability high cancers: updated analysis of the phase II KEYNOTE-164 and KEYNOTE-158 studies. Ann. Oncol., 2019, 30, v475.
[http://dx.doi.org/10.1093/annonc/mdz253]

Drilon, A.; Laetsch, T.W.; Kummar, S.; DuBois, S.G.; Lassen, U.N.; Demetri, G.D.; Nathenson, M.; Doebele, R.C.; Farago, A.F.; Pappo, A.S.; Turpin, B.; Dowlati, A.; Brose, M.S.; Mascarenhas, L.; Federman, N.; Berlin, J.; El-Deiry, W.S.; Baik, C.; Deeken, J.; Boni, V.; Nagasubramanian, R.; Taylor, M.; Rudzinski, E.R.; Meric-Bernstam, F.; Sohal, D.P.S.; Ma, P.C.; Raez, L.E.; Hechtman, J.F.; Benayed, R.; Ladanyi, M.; Tuch, B.B.; Ebata, K.; Cruickshank, S.; Ku, N.C.; Cox, M.C.; Hawkins, D.S.; Hong, D.S.; Hyman, D.M. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N. Engl. J. Med., 2018, 378(8), 731-739.
[http://dx.doi.org/10.1056/NEJMoa1714448] [PMID: 29466156]

Tan, D.S.W.; Lassen, U.N.; Albert, C.M.; Kummar, S.; van Tilburg, C.; Dubois, S.G. Larotrectinib efficacy and safety in TRK fusion cancer: an expanded clinical dataset showing consistency in an age and tumor agnostic approach.Ann. Oncol., 2018, 29(suppl_8), mdy279-397.,

Garber, K. Tissue-agnostic cancer drug pipeline grows, despite doubts. Nat. Rev. Drug Discov., 2018, 17(4), 227-229.
[http://dx.doi.org/10.1038/nrd.2018.6] [PMID: 29520093]

Subbiah, V.; Gainor, J.F.; Rahal, R.; Brubaker, J.D.; Kim, J.L.; Maynard, M.; Hu, W.; Cao, Q.; Sheets, M.P.; Wilson, D.; Wilson, K.J.; DiPietro, L.; Fleming, P.; Palmer, M.; Hu, M.I.; Wirth, L.; Brose, M.S.; Ou, S.I.; Taylor, M.; Garralda, E.; Miller, S.; Wolf, B.; Lengauer, C.; Guzi, T.; Evans, E.K. Precision targeted therapy with BLU-667 for RET-driven cancers. Cancer Discov., 2018, 8(7), 836-849.
[http://dx.doi.org/10.1158/2159-8290.CD-18-0338] [PMID: 29657135]

Lih, C.J.; Sims, D.J.; Harrington, R.D.; Polley, E.C.; Zhao, Y.; Mehaffey, M.G.; Forbes, T.D.; Das, B.; Walsh, W.D.; Datta, V.; Harper, K.N.; Bouk, C.H.; Rubinstein, L.V.; Simon, R.M.; Conley, B.A.; Chen, A.P.; Kummar, S.; Doroshow, J.H.; Williams, P.M. Analytical validation and application of a targeted next-generation sequencing mutation-detection assay for use in treatment assignment in the NCI-MPACT trial. J. Mol. Diagn., 2016, 18(1), 51-67.
[http://dx.doi.org/10.1016/j.jmoldx.2015.07.006] [PMID: 26602013]

Lih, C.J.; Takebe, N. Considerations of developing an NGS assay for clinical applications in precision oncology: the NCI-MATCH NGS assay experience. Curr. Probl. Cancer, 2017, 41(3), 201-211.
[http://dx.doi.org/10.1016/j.currproblcancer.2017.05.003] [PMID: 28625332]

Dienstmann, R.; Rodon, J.; Barretina, J.; Tabernero, J. Genomic medicine frontier in human solid tumors: prospects and challenges. J. Clin. Oncol., 2013, 31(15), 1874-1884.
[http://dx.doi.org/10.1200/JCO.2012.45.2268] [PMID: 23589551]

Jung, Y.S.; Park, J. Il. Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond β-catenin and the destruction complex. Exp. Mol. Med., 2020, 52, 183-191.

Martin-Orozco, E.; Sanchez-Fernandez, A.; Ortiz-Parra, I.; Ayala-San Nicolas, M. WNT signaling in tumors: the way to evade drugs and immunity. Front. Immunol., 2019, 10, 2854.
[http://dx.doi.org/10.3389/fimmu.2019.02854] [PMID: 31921125]

Zhang, Y.; Zu, D.; Chen, Z.; Ying, G. An update on Wnt signaling pathway in cancer. Transl. Cancer Res., 2020, 9(2), 1246-1252.
[http://dx.doi.org/10.21037/tcr.2019.12.50]

Chen, M.; Wang, J.; Lu, J.; Bond, M.C.; Ren, X-R.; Lyerly, H.K.; Barak, L.S.; Chen, W. The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling. Bone, 2012, 48(43), 10267-10274.

Koval, A.V.; Vlasov, P.; Shichkova, P.; Khunderyakova, S.; Markov, Y.; Panchenko, J.; Volodina, A.; Kondrashov, F.A.; Katanaev, V.L. Anti-leprosy drug clofazimine inhibits growth of triple-negative breast cancer cells via inhibition of canonical Wnt signaling. Biochem. Pharmacol., 2014, 87(4), 571-578.
[http://dx.doi.org/10.1016/j.bcp.2013.12.007] [PMID: 24355563]

Guimaraes, P.P.G.; Tan, M.; Tammela, T.; Wu, K.; Chung, A.; Oberli, M.; Wang, K.; Spektor, R.; Riley, R.S.; Viana, C.T.R.; Jacks, T.; Langer, R.; Mitchell, M.J. Potent in vivo lung cancer Wnt signaling inhibition via cyclodextrin-LGK974 inclusion complexes. J. Control. Release, 2018, 290, 75-87.
[http://dx.doi.org/10.1016/j.jconrel.2018.09.025] [PMID: 30290244]

Thomson, D.W.; Wagner, A.J.; Bantscheff, M.; Benson, R.E.; Dittus, L.; Duempelfeld, B.; Drewes, G.; Krause, J.; Moore, J.T.; Mueller, K.; Poeckel, D.; Rau, C.; Salzer, E.; Shewchuk, L.; Hopf, C.; Emery, J.G.; Muelbaier, M. Discovery of a highly selective tankyrase inhibitor displaying growth inhibition effects against a diverse range of tumor derived cell lines. J. Med. Chem., 2017, 60(13), 5455-5471.
[http://dx.doi.org/10.1021/acs.jmedchem.7b00137] [PMID: 28591512]

HHS Public, Access. Physiol. Behav., 2016, 35(28), 3705-3717.

Gurney, A.; Axelrod, F.; Bond, C.J.; Cain, J.; Chartier, C.; Donigan, L.; Fischer, M.; Chaudhari, A.; Ji, M.; Kapoun, A.M.; Lam, A.; Lazetic, S.; Ma, S.; Mitra, S.; Park, I.K.; Pickell, K.; Sato, A.; Satyal, S.; Stroud, M.; Tran, H.; Yen, W.C.; Lewicki, J.; Hoey, T. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc. Natl. Acad. Sci. USA, 2012, 109(29), 11717-11722.
[http://dx.doi.org/10.1073/pnas.1120068109] [PMID: 22753465]

Guo, H.; Lu, Y.; Wang, J.; Liu, X.; Keller, E.T.; Liu, Q.; Zhou, Q.; Zhang, J. Targeting the Notch signaling pathway in cancer therapeutics. Thorac. Cancer, 2014, 5(6), 473-486.
[http://dx.doi.org/10.1111/1759-7714.12143] [PMID: 26767041]

Ellisen, L.W.; Bird, J.; West, D.C.; Soreng, A.L.; Reynolds, T.C.; Smith, S.D.; Sklar, J. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell, 1991, 66(4), 649-661.
[http://dx.doi.org/10.1016/0092-8674(91)90111-B] [PMID: 1831692]

Katoh, M.; Katoh, M. Precision medicine for human cancers with Notch signaling dysregulation. Review Int. J. Mol. Med., 2020, 45(2), 279-297.
[PMID: 31894255]

Rosati, E.; Sabatini, R.; De Falco, F.; Del Papa, B.; Falzetti, F.; Di Ianni, M.; Cavalli, L.; Fettucciari, K.; Bartoli, A.; Screpanti, I.; Marconi, P. γ-Secretase inhibitor I induces apoptosis in chronic lymphocytic leukemia cells by proteasome inhibition, endoplasmic reticulum stress increase and notch down-regulation. Int. J. Cancer, 2013, 132(8), 1940-1953.
[http://dx.doi.org/10.1002/ijc.27863] [PMID: 23001755]

Huynh, C.; Poliseno, L.; Segura, M.F.; Medicherla, R.; Haimovic, A.; Menendez, S.; Shang, S.; Pavlick, A.; Shao, Y.; Darvishian, F.; Boylan, J.F.; Osman, I.; Hernando, E. The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma. PLoS One, 2011, 6(9)e25264
[http://dx.doi.org/10.1371/journal.pone.0025264] [PMID: 21980408]

Tilly, H.; Morschhauser, F.; Bartlett, N.L.; Mehta, A.; Salles, G.; Haioun, C.; Munoz, J.; Chen, A.I.; Kolibaba, K.; Lu, D.; Yan, M.; Penuel, E.; Hirata, J.; Lee, C.; Sharman, J.P. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study. Lancet Oncol., 2019, 20(7), 998-1010.
[http://dx.doi.org/10.1016/S1470-2045(19)30091-9] [PMID: 31101489]

Horwitz, S.; O’Connor, O.A.; Pro, B.; Illidge, T.; Fanale, M.; Advani, R.; Bartlett, N.L.; Christensen, J.H.; Morschhauser, F.; Domingo-Domenech, E.; Rossi, G.; Kim, W.S.; Feldman, T.; Lennard, A.; Belada, D.; Illés, Á.; Tobinai, K.; Tsukasaki, K.; Yeh, S.P.; Shustov, A.; Hüttmann, A.; Savage, K.J.; Yuen, S.; Iyer, S.; Zinzani, P.L.; Hua, Z.; Little, M.; Rao, S.; Woolery, J.; Manley, T.; Trümper, L. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet, 2019, 393(10168), 229-240.
[http://dx.doi.org/10.1016/S0140-6736(18)32984-2] [PMID: 30522922]

Kantarjian, H.M.; DeAngelo, D.J.; Stelljes, M.; Martinelli, G.; Liedtke, M.; Stock, W.; Gökbuget, N.; O’Brien, S.; Wang, K.; Wang, T.; Paccagnella, M.L.; Sleight, B.; Vandendries, E.; Advani, A.S. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N. Engl. J. Med., 2016, 375(8), 740-753.
[http://dx.doi.org/10.1056/NEJMoa1509277] [PMID: 27292104]

Dong, X.; Lin, Q.; Aihara, A.; Li, Y.; Huang, C.K.; Chung, W.; Tang, Q.; Chen, X.; Carlson, R.; Nadolny, C.; Gabriel, G.; Olsen, M.; Wands, J.R. Aspartate β-Hydroxylase expression promotes a malignant pancreatic cellular phenotype. Oncotarget, 2015, 6(2), 1231-1248.
[http://dx.doi.org/10.18632/oncotarget.2840] [PMID: 25483102]

Sureban, S.M.; May, R.; Mondalek, F.G.; Qu, D.; Ponnurangam, S.; Pantazis, P.; Anant, S.; Ramanujam, R.P.; Houchen, C.W. Nanoparticle-based delivery of siDCAMKL-1 increases microRNA-144 and inhibits colorectal cancer tumor growth via a Notch-1 dependent mechanism. J. Nanobiotechnology, 2011, 9(1), 40.
[http://dx.doi.org/10.1186/1477-3155-9-40] [PMID: 21929751]

Kobia, F.; Duchi, S.; Deflorian, G.; Vaccari, T. Pharmacologic inhibition of vacuolar H+ ATPase reduces physiologic and oncogenic Notch signaling. Mol. Oncol., 2014, 8(2), 207-220.
[http://dx.doi.org/10.1016/j.molonc.2013.11.002] [PMID: 24309677]

Johnson, R.L.; Rothman, A.L.; Xie, J.; Goodrich, L.V.; Bare, J.W.; Bonifas, J.M. Human homolog of patched, a candidate gene for the basal cell nevus syndrome.Science (80- ), 1996, 272(5268), 1668-1671.,
[http://dx.doi.org/10.1126/science.272.5268.1668]

Cooper, M.K.; Porter, J.A.; Young, K.E.; Beachy, P.A. Teratogen-mediated inhibition of target tissue response to Shh signaling.Science (80-), 1998, 280(5369), 1603-1607.,
[http://dx.doi.org/10.1126/science.280.5369.1603]

Onishi, H.; Katano, M. Hedgehog signaling pathway as a therapeutic target in various types of cancer. Cancer Sci., 2011, 102(10), 1756-1760.
[http://dx.doi.org/10.1111/j.1349-7006.2011.02010.x] [PMID: 21679342]

Wu, F.; Zhang, Y.; Sun, B.; McMahon, A.P.; Wang, Y. Hedgehog signaling: from basic biology to cancer therapy. Cell Chem. Biol., 2017, 24(3), 252-280.
[http://dx.doi.org/10.1016/j.chembiol.2017.02.010] [PMID: 28286127]

Engelman, J.A.; Luo, J.; Cantley, L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet., 2006, 7(8), 606-619.
[http://dx.doi.org/10.1038/nrg1879] [PMID: 16847462]

Forbes, S.A.; Bhamra, G.; Bamford, S.; Dawson, E.; Kok, C.; Clements, J.; Menzies, A.; Teague, J.W.; Futreal, P.A.; Stratton, M.R. The catalogue of somatic mutations in cancer (COSMIC). Curr. Protoc. Hum. Genet., 2008, Chapter 10(1), 11;
[http://dx.doi.org/10.1002/0471142905.hg1011s57] [PMID: 18428421]

Yang, J.; Nie, J.; Ma, X.; Wei, Y.; Peng, Y.; Wei, X. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol. Cancer, 2019, 18(1), 26.
[http://dx.doi.org/10.1186/s12943-019-0954-x] [PMID: 30782187]

Maira, S.M.; Pecchi, S.; Huang, A.; Burger, M.; Knapp, M.; Sterker, D.; Schnell, C.; Guthy, D.; Nagel, T.; Wiesmann, M.; Brachmann, S.; Fritsch, C.; Dorsch, M.; Chène, P.; Shoemaker, K.; De Pover, A.; Menezes, D.; Martiny-Baron, G.; Fabbro, D.; Wilson, C.J.; Schlegel, R.; Hofmann, F.; García-Echeverría, C.; Sellers, W.R.; Voliva, C.F. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol. Cancer Ther., 2012, 11(2), 317-328.
[http://dx.doi.org/10.1158/1535-7163.MCT-11-0474] [PMID: 22188813]

Dong, S.; Guinn, D.; Dubovsky, J.A.; Zhong, Y.; Lehman, A.; Kutok, J.; Woyach, J.A.; Byrd, J.C.; Johnson, A.J. IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells. Blood, 2014, 124(24), 3583-3586.
[http://dx.doi.org/10.1182/blood-2014-07-587279] [PMID: 25258342]

Fritsch, C.; Huang, A.; Chatenay-Rivauday, C.; Schnell, C.; Reddy, A.; Liu, M.; Kauffmann, A.; Guthy, D.; Erdmann, D.; De Pover, A.; Furet, P.; Gao, H.; Ferretti, S.; Wang, Y.; Trappe, J.; Brachmann, S.M.; Maira, S.M.; Wilson, C.; Boehm, M.; Garcia-Echeverria, C.; Chene, P.; Wiesmann, M.; Cozens, R.; Lehar, J.; Schlegel, R.; Caravatti, G.; Hofmann, F.; Sellers, W.R. Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol. Cancer Ther., 2014, 13(5), 1117-1129.
[http://dx.doi.org/10.1158/1535-7163.MCT-13-0865] [PMID: 24608574]

van Geel, R.M.J.M.; Tabernero, J.; Elez, E.; Bendell, J.C.; Spreafico, A.; Schuler, M.; Yoshino, T.; Delord, J.P.; Yamada, Y.; Lolkema, M.P.; Faris, J.E.; Eskens, F.A.L.M.; Sharma, S.; Yaeger, R.; Lenz, H.J.; Wainberg, Z.A.; Avsar, E.; Chatterjee, A.; Jaeger, S.; Tan, E.; Maharry, K.; Demuth, T.; Schellens, J.H.M. A phase Ib dose-escalation study of encorafenib and cetuximab with or without alpelisib in metastatic BRAF-mutant colorectal cancer. Cancer Discov., 2017, 7(6), 610-619.
[http://dx.doi.org/10.1158/2159-8290.CD-16-0795] [PMID: 28363909]

Gopal, A.K.; Kahl, B.S.; de Vos, S.; Wagner-Johnston, N.D.; Schuster, S.J.; Jurczak, W.J.; Flinn, I.W.; Flowers, C.R.; Martin, P.; Viardot, A.; Blum, K.A.; Goy, A.H.; Davies, A.J.; Zinzani, P.L.; Dreyling, M.; Johnson, D.; Miller, L.L.; Holes, L.; Li, D.; Dansey, R.D.; Godfrey, W.R.; Salles, G.A. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N. Engl. J. Med., 2014, 370(11), 1008-1018.
[http://dx.doi.org/10.1056/NEJMoa1314583] [PMID: 24450858]

Kondapaka, S.B.; Singh, S.S.; Dasmahapatra, G.P.; Sausville, E.A.; Roy, K.K. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol. Cancer Ther., 2003, 2(11), 1093-1103.
[PMID: 14617782]

Hennessy, B.T.; Smith, D.L.; Ram, P.T.; Lu, Y.; Mills, G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov., 2005, 4(12), 988-1004.
[http://dx.doi.org/10.1038/nrd1902] [PMID: 16341064]

Orton, R.J.; Sturm, O.E.; Vyshemirsky, V.; Calder, M.; Gilbert, D.R.; Kolch, W. Computational modelling of the receptor-tyrosine-kinase-activated MAPK pathway. Biochem. J., 2005, 392(Pt 2), 249-261.
[http://dx.doi.org/10.1042/BJ20050908] [PMID: 16293107]

Takeda, H.; Nishikawa, H.; Osaki, Y. The new era of precision medicine in hepatocellular carcinoma: the urgent need for promising biomarkers. Hepatobiliary Surg. Nutr., 2018, 7(6), 490-491.
[http://dx.doi.org/10.21037/hbsn.2018.08.06] [PMID: 30652097]

Degirmenci, U.; Wang, M.; Hu, J. Targeting aberrant RAS/RAF/MEK/ERK signaling for cancer therapy. Cells, 2020, 9(1), 198.

Smalley, I.; Smalley, K.S.M. ERK inhibition: a new front in the war against mapk pathway-driven cancers? Cancer Discov., 2018, 8(2), 140-142.
[http://dx.doi.org/10.1158/2159-8290.CD-17-1355] [PMID: 29431672]

Dahlman, K.B.; Xia, J.; Hutchinson, K.; Ng, C.; Hucks, D.; Jia, P.; Atefi, M.; Su, Z.; Branch, S.; Lyle, P.L.; Hicks, D.J.; Bozon, V.; Glaspy, J.A.; Rosen, N.; Solit, D.B.; Netterville, J.L.; Vnencak-Jones, C.L.; Sosman, J.A.; Ribas, A.; Zhao, Z.; Pao, W. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov., 2012, 2(9), 791-797.
[http://dx.doi.org/10.1158/2159-8290.CD-12-0097] [PMID: 22798288]

Malumbres, M.; Barbacid, M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer, 2009, 9(3), 153-166.
[http://dx.doi.org/10.1038/nrc2602] [PMID: 19238148]

Buolamwini, J.K. Cell cycle molecular targets in novel anticancer drug discovery. Curr. Pharm. Des., 2000, 6(4), 379-392.
[http://dx.doi.org/10.2174/1381612003400948] [PMID: 10788588]

Finn, R.S.; Crown, J.P.; Lang, I.; Boer, K.; Bondarenko, I.M.; Kulyk, S.O.; Ettl, J.; Patel, R.; Pinter, T.; Schmidt, M.; Shparyk, Y.; Thummala, A.R.; Voytko, N.L.; Fowst, C.; Huang, X.; Kim, S.T.; Randolph, S.; Slamon, D.J. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol., 2015, 16(1), 25-35.
[http://dx.doi.org/10.1016/S1470-2045(14)71159-3] [PMID: 25524798]

Meijer, L.; Raymond, E. Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc. Chem. Res., 2003, 36(6), 417-425.
[http://dx.doi.org/10.1021/ar0201198] [PMID: 12809528]

Wang, L-M.; Ren, D-M. Flavopiridol, the first cyclin-dependent kinase inhibitor: recent advances in combination chemotherapy. Mini Rev. Med. Chem., 2010, 10(11), 1058-1070.
[http://dx.doi.org/10.2174/1389557511009011058] [PMID: 21047304]

Manfredi, M.G.; Ecsedy, J.A.; Chakravarty, A.; Silverman, L.; Zhang, M.; Hoar, K.M.; Stroud, S.G.; Chen, W.; Shinde, V.; Huck, J.J.; Wysong, D.R.; Janowick, D.A.; Hyer, M.L.; Leroy, P.J.; Gershman, R.E.; Silva, M.D.; Germanos, M.S.; Bolen, J.B.; Claiborne, C.F.; Sells, T.B. Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin. Cancer Res., 2011, 17(24), 7614-7624.
[http://dx.doi.org/10.1158/1078-0432.CCR-11-1536] [PMID: 22016509]

Otto, T.; Sicinski, P. Cell cycle proteins as promising targets in cancer therapy. Nat. Rev. Cancer, 2017, 17(2), 93-115.
[http://dx.doi.org/10.1038/nrc.2016.138] [PMID: 28127048]

Anderson, R.T.; Keysar, S.B.; Bowles, D.W.; Glogowska, M.J.; Astling, D.P.; Morton, J.J.; Le, P.; Umpierrez, A.; Eagles-Soukup, J.; Gan, G.N.; Vogler, B.W.; Sehrt, D.; Takimoto, S.M.; Aisner, D.L.; Wilhelm, F.; Frederick, B.A.; Varella-Garcia, M.; Tan, A.C.; Jimeno, A. The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas. Mol. Cancer Ther., 2013, 12(10), 1994-2005.
[http://dx.doi.org/10.1158/1535-7163.MCT-13-0206] [PMID: 23873848]

Rudolph, D.; Steegmaier, M.; Hoffmann, M.; Grauert, M.; Baum, A.; Quant, J.; Haslinger, C.; Garin-Chesa, P.; Adolf, G.R. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin. Cancer Res., 2009, 15(9), 3094-3102.
[http://dx.doi.org/10.1158/1078-0432.CCR-08-2445] [PMID: 19383823]

Sugarman, E.T.; Zhang, G.; Shay, J.W. In perspective: an update on telomere targeting in cancer. Mol. Carcinog., 2019, 58(9), 1581-1588.
[http://dx.doi.org/10.1002/mc.23035] [PMID: 31062416]

Asai, A.; Oshima, Y.; Yamamoto, Y.; Uochi, T.A.; Kusaka, H.; Akinaga, S.; Yamashita, Y.; Pongracz, K.; Pruzan, R.; Wunder, E.; Piatyszek, M.; Li, S.; Chin, A.C.; Harley, C.B.; Gryaznov, S. A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res., 2003, 63(14), 3931-3939.
[PMID: 12873987]

Thompson, P.A.; Drissi, R.; Muscal, J.A.; Panditharatna, E.; Fouladi, M.; Ingle, A.M.; Ahern, C.H.; Reid, J.M.; Lin, T.; Weigel, B.J.; Blaney, S.M. A phase I trial of imetelstat in children with refractory or recurrent solid tumors: a Children’s Oncology Group Phase I Consortium Study (ADVL1112). Clin. Cancer Res., 2013, 19(23), 6578-6584.
[http://dx.doi.org/10.1158/1078-0432.CCR-13-1117] [PMID: 24097866]

Ding, X.; Cheng, J.; Pang, Q.; Wei, X.; Zhang, X.; Wang, P.; Yuan, Z.; Qian, D. BIBR1532, a selective telomerase inhibitor, enhances radiosensitivity of non-small cell lung cancer through increasing telomere dysfunction and ATM/CHK1 inhibition. Int. J. Radiat. Oncol. Biol. Phys., 2019, 105(4), 861-874.
[http://dx.doi.org/10.1016/j.ijrobp.2019.08.009] [PMID: 31419512]

Bauer, N.C.; Corbett, A.H.; Doetsch, P.W. The current state of eukaryotic DNA base damage and repair. Nucleic Acids Res., 2015, 43(21), 10083-10101.
[http://dx.doi.org/10.1093/nar/gkv1136] [PMID: 26519467]

Rainey, M.D.; Charlton, M.E.; Stanton, R.V.; Kastan, M.B. Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. Cancer Res., 2008, 68(18), 7466-7474.
[http://dx.doi.org/10.1158/0008-5472.CAN-08-0763] [PMID: 18794134]

Zabludoff, S.D.; Deng, C.; Grondine, M.R.; Sheehy, A.M.; Ashwell, S.; Caleb, B.L.; Green, S.; Haye, H.R.; Horn, C.L.; Janetka, J.W.; Liu, D.; Mouchet, E.; Ready, S.; Rosenthal, J.L.; Queva, C.; Schwartz, G.K.; Taylor, K.J.; Tse, A.N.; Walker, G.E.; White, A.M. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol. Cancer Ther., 2008, 7(9), 2955-2966.
[http://dx.doi.org/10.1158/1535-7163.MCT-08-0492] [PMID: 18790776]

Ding, Q.; Zhang, Z.; Liu, J.J.; Jiang, N.; Zhang, J.; Ross, T.M.; Chu, X.J.; Bartkovitz, D.; Podlaski, F.; Janson, C.; Tovar, C.; Filipovic, Z.M.; Higgins, B.; Glenn, K.; Packman, K.; Vassilev, L.T.; Graves, B. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J. Med. Chem., 2013, 56(14), 5979-5983.
[http://dx.doi.org/10.1021/jm400487c] [PMID: 23808545]

Chen, S.; Yuan, X.; Xu, H.; Yi, M.; Liu, S.; Wen, F. WNT974 inhibits proliferation, induces apoptosis, and enhances chemosensitivity to doxorubicin in lymphoma cells by inhibiting Wnt/β-catenin signaling. Med. Sci. Monit., 2020, 26e923799
[PMID: 32597418]

Madan, B.; Ke, Z.; Harmston, N.; Ho, S.Y.; Frois, A.O.; Alam, J. Wnt addiction of genetically defined cancers reversed by PORCN inhibition. Oncogene, 2016, 35(17), 2197-2207.
[http://dx.doi.org/10.1038/onc.2015.280]

Liu, J.; Pan, S.; Hsieh, M.H.; Ng, N.; Sun, F.; Wang, T.; Kasibhatla, S.; Schuller, A.G.; Li, A.G.; Cheng, D.; Li, J.; Tompkins, C.; Pferdekamper, A.; Steffy, A.; Cheng, J.; Kowal, C.; Phung, V.; Guo, G.; Wang, Y.; Graham, M.P.; Flynn, S.; Brenner, J.C.; Li, C.; Villarroel, M.C.; Schultz, P.G.; Wu, X.; McNamara, P.; Sellers, W.R.; Petruzzelli, L.; Boral, A.L.; Seidel, H.M.; McLaughlin, M.E.; Che, J.; Carey, T.E.; Vanasse, G.; Harris, J.L. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc. Natl. Acad. Sci. USA, 2013, 110(50), 20224-20229.
[http://dx.doi.org/10.1073/pnas.1314239110] [PMID: 24277854]

Jimeno, A.; Gordon, M.; Chugh, R.; Messersmith, W.; Mendelson, D.; Dupont, J.; Stagg, R.; Kapoun, A.M.; Xu, L.; Uttamsingh, S.; Brachmann, R.K.; Smith, D.C. A first-in-human phase I study of the anticancer stem cell agent ipafricept (OMP-54F28), a decoy receptor for wnt ligands, in patients with advanced solid tumors. Clin. Cancer Res., 2017, 23(24), 7490-7497.
[http://dx.doi.org/10.1158/1078-0432.CCR-17-2157] [PMID: 28954784]

Lenz, H.J.; Kahn, M. Safely targeting cancer stem cells via selective catenin coactivator antagonism. Cancer Sci., 2014, 105(9), 1087-1092.
[http://dx.doi.org/10.1111/cas.12471] [PMID: 24975284]

Yu, J.; Chen, Y.; Chen, L.; Zhang, L.; Rassenti, L.Z.; Widhopf, G.F., II; Kipps, T.J. Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma. Oncotarget, 2018, 9(37), 24731-24736.
[http://dx.doi.org/10.18632/oncotarget.25340] [PMID: 29872501]

Scarborough, H.A.; Helfrich, B.A.; Casás-Selves, M.; Schuller, A.G.; Grosskurth, S.E.; Kim, J.; Tan, A.C.; Chan, D.C.; Zhang, Z.; Zaberezhnyy, V.; Bunn, P.A.; DeGregori, J. AZ1366: an inhibitor of tankyrase and the canonical wnt pathway that limits the persistence of non-small cell lung cancer cells following EGFR inhibition. Clin. Cancer Res., 2017, 23(6), 1531-1541.
[http://dx.doi.org/10.1158/1078-0432.CCR-16-1179] [PMID: 27663586]

Fulciniti, M.; Tassone, P.; Hideshima, T.; Vallet, S.; Nanjappa, P.; Ettenberg, S.A.; Shen, Z.; Patel, N.; Tai, Y.T.; Chauhan, D.; Mitsiades, C.; Prabhala, R.; Raje, N.; Anderson, K.C.; Stover, D.R.; Munshi, N.C. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood, 2009, 114(2), 371-379.
[http://dx.doi.org/10.1182/blood-2008-11-191577] [PMID: 19417213]

Shan, J.; Shi, D.L.; Wang, J.; Zheng, J. Identification of a specific inhibitor of the dishevelled PDZ domain. Biochemistry, 2005, 44(47), 15495-15503.
[http://dx.doi.org/10.1021/bi0512602] [PMID: 16300398]

Yang, Q.; Chen, L.S.; Ha, M.J.; Do, K.A.; Neelapu, S.S.; Gandhi, V. Idelalisib impacts cell growth through inhibiting translation-regulatory mechanisms in mantle cell lymphoma. Clin. Cancer Res., 2017, 23(1), 181-192.
[http://dx.doi.org/10.1158/1078-0432.CCR-15-3135] [PMID: 27342398]

Fruman, D.A.; Cantley, L.C. Idelalisib-a PI3Kδ inhibitor for B-cell cancers. N. Engl. J. Med., 2014, 370(11), 1061-1062.
[http://dx.doi.org/10.1056/NEJMe1400055] [PMID: 24620870]

Folkes, A.J.; Alderton, W.K.; Alix, S.; Baker, S.J.; Box, G.; Chuckowree, I.S.; Clarke, P.A.; Eccles, S.A.; Friedman, L.S.; Hayes, A.; Hancox, T.C.; Kugendradas, A.; Moore, P.; Olivero, A.G.; Pang, J.; Patel, S.; Pergl-Wilson, G.H.; Robson, A.; Saghir, N.; Salphati, L.; Sohal, S.; Ultsch, M.H.; Wallweber, H.J.A.; Wan, N.C.; Wiesmann, C.; Workman, P.; Zhyvoloup, A.; Shuttleworth, S.J. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J. Med. Chem., 2008, 51, 11.

Foster, P.; Yamaguchi, K.; Hsu, P.P.; Qian, F.; Du, X.; Wu, J.; Won, K.A.; Yu, P.; Jaeger, C.T.; Zhang, W.; Marlowe, C.K.; Keast, P.; Abulafia, W.; Chen, J.; Young, J.; Plonowski, A.; Yakes, F.M.; Chu, F.; Engell, K.; Bentzien, F.; Lam, S.T.; Dale, S.; Yturralde, O.; Matthews, D.J.; Lamb, P.; Laird, A.D. The selective PI3K inhibitor XL147 (SAR245408) inhibits tumor growth and survival and potentiates the activity of chemotherapeutic agents in preclinical tumor models. Mol. Cancer Ther., 2015, 14(4), 931-940.
[http://dx.doi.org/10.1158/1535-7163.MCT-14-0833] [PMID: 25637314]

Jiang, H.; Fan, D.; Zhou, G.; Li, X.; Deng, H. Phosphatidylinositol 3-kinase inhibitor(LY294002) induces apoptosis of human nasopharyngeal carcinoma in vitro and in vivo. J. Exp. Clin. Cancer Res., 2010, 29(1), 34.
[http://dx.doi.org/10.1186/1756-9966-29-34] [PMID: 20412566]

Davies, B.R.; Greenwood, H.; Dudley, P.; Crafter, C.; Yu, D.H.; Zhang, J.; Li, J.; Gao, B.; Ji, Q.; Maynard, J.; Ricketts, S.A.; Cross, D.; Cosulich, S.; Chresta, C.C.; Page, K.; Yates, J.; Lane, C.; Watson, R.; Luke, R.; Ogilvie, D.; Pass, M. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol. Cancer Ther., 2012, 11(4), 873-887.
[http://dx.doi.org/10.1158/1535-7163.MCT-11-0824-T] [PMID: 22294718]

Saura, C.; Roda, D.; Roselló, S.; Oliveira, M.; Macarulla, T.; Pérez-Fidalgo, J.A.; Morales-Barrera, R.; Sanchis-García, J.M.; Musib, L.; Budha, N.; Zhu, J.; Nannini, M.; Chan, W.Y.; Sanabria Bohórquez, S.M.; Meng, R.D.; Lin, K.; Yan, Y.; Patel, P.; Baselga, J.; Tabernero, J.; Cervantes, A. A first-in-human phase I study of the ATP-competitive AKT inhibitor Ipatasertib demonstrates Robust and safe targeting of AKT in patients with solid tumors. Cancer Discov., 2017, 7(1), 102-113.
[http://dx.doi.org/10.1158/2159-8290.CD-16-0512] [PMID: 27872130]

Sun, L.; Huang, Y.; Liu, Y.; Zhao, Y.; He, X.; Zhang, L. Ipatasertib, a novel Akt inhibitor, induces transcription factor FoxO3a and NF-κB directly regulates PUMA-dependent apoptosis. Cell Death Dis., 2018, 9(9), 1-13.
[http://dx.doi.org/10.1038/s41419-018-0943-9]

Pinton, G.; Manente, A.G.; Angeli, G.; Mutti, L.; Moro, L. Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesothelioma. PLoS One, 2012, 7(5)e36856
[http://dx.doi.org/10.1371/journal.pone.0036856] [PMID: 22590625]

Imrali, A.; Mao, X.; Yeste-Velasco, M.; Shamash, J.; Lu, Y. Rapamycin inhibits prostate cancer cell growth through cyclin D1 and enhances the cytotoxic efficacy of cisplatin. Am. J. Cancer Res., 2016, 6(8), 1772-1784.
[PMID: 27648364]

Mabuchi, S.; Altomare, D.A.; Connolly, D.C.; Klein-Szanto, A.; Litwin, S.; Hoelzle, M.K.; Hensley, H.H.; Hamilton, T.C.; Testa, J.R. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res., 2007, 67(6), 2408-2413.
[http://dx.doi.org/10.1158/0008-5472.CAN-06-4490] [PMID: 17363557]

Shi, F.; Zhang, J.; Liu, H.; Wu, L.; Jiang, H.; Wu, Q.; Liu, T.; Lou, M.; Wu, H. The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo. Oncotarget, 2017, 9(1), 706-717.
[http://dx.doi.org/10.18632/oncotarget.23091] [PMID: 29416647]

Chresta, C.M.; Davies, B.R.; Hickson, I.; Harding, T.; Cosulich, S.; Critchlow, S.E.; Vincent, J.P.; Ellston, R.; Jones, D.; Sini, P.; James, D.; Howard, Z.; Dudley, P.; Hughes, G.; Smith, L.; Maguire, S.; Hummersone, M.; Malagu, K.; Menear, K.; Jenkins, R.; Jacobsen, M.; Smith, G.C.; Guichard, S.; Pass, M. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res., 2010, 70(1), 288-298.
[http://dx.doi.org/10.1158/0008-5472.CAN-09-1751] [PMID: 20028854]

Hertzman Johansson, C.; Egyhazi Brage, S. BRAF inhibitors in cancer therapy. Pharmacol. Ther., 2014, 142(2), 176-182.
[http://dx.doi.org/10.1016/j.pharmthera.2013.11.011] [PMID: 24325952]

Wright, C.J.M.; McCormack, P.L. Trametinib: first global approval. Drugs, 2013, 73(11), 1245-1254.
[http://dx.doi.org/10.1007/s40265-013-0096-1] [PMID: 23846731]

Han, K.; Jin, J.Y.; Marchand, M.; Eppler, S.; Choong, N.; Hack, S.P.; Tikoo, N.; Bruno, R.; Dresser, M.; Musib, L.; Budha, N.R. Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors. Cancer Chemother. Pharmacol., 2015, 76(5), 917-924.
[http://dx.doi.org/10.1007/s00280-015-2862-0] [PMID: 26365290]

Woodfield, S.E.; Zhang, L.; Scorsone, K.A.; Liu, Y.; Zage, P.E. Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression. BMC Cancer, 2016, 16(1), 172.
[http://dx.doi.org/10.1186/s12885-016-2199-z] [PMID: 26925841]

Ciombor, K.K.; Bekaii-Saab, T. Selumetinib for the treatment of cancer. Expert Opin. Investig. Drugs, 2015, 24(1), 111-123.
[http://dx.doi.org/10.1517/13543784.2015.982275] [PMID: 25385055]

Germann, U.A.; Furey, B.F.; Markland, W.; Hoover, R.R.; Aronov, A.M.; Roix, J.J.; Hale, M.; Boucher, D.M.; Sorrell, D.A.; Martinez-Botella, G.; Fitzgibbon, M.; Shapiro, P.; Wick, M.J.; Samadani, R.; Meshaw, K.; Groover, A.; DeCrescenzo, G.; Namchuk, M.; Emery, C.M.; Saha, S.; Welsch, D.J. Targeting the MAPK signaling pathway in cancer: promising preclinical activity with the novel selective ERK1/2 inhibitor BVD-523 (ulixertinib). Mol. Cancer Ther., 2017, 16(11), 2351-2363.
[http://dx.doi.org/10.1158/1535-7163.MCT-17-0456] [PMID: 28939558]

Barok, M.; Joensuu, H.; Isola, J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res., 2014, 16(2), 209.
[http://dx.doi.org/10.1186/bcr3621] [PMID: 24887180]

Valabrega, G.; Montemurro, F.; Aglietta, M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann. Oncol., 2007, 18(6), 977-984.
[http://dx.doi.org/10.1093/annonc/mdl475] [PMID: 17229773]

Smith, D.C.; Eisenberg, P.D.; Manikhas, G.; Chugh, R.; Gubens, M.A.; Stagg, R.J.; Kapoun, A.M.; Xu, L.; Dupont, J.; Sikic, B. A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors. Clin. Cancer Res., 2014, 20(24), 6295-6303.
[http://dx.doi.org/10.1158/1078-0432.CCR-14-1373] [PMID: 25324140]

Mancarella, S.; Serino, G.; Dituri, F.; Cigliano, A.; Ribback, S.; Wang, J.; Chen, X.; Calvisi, D.F.; Giannelli, G. Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis. Cell Death Differ., 2020, 27(8), 2330-2343.
[http://dx.doi.org/10.1038/s41418-020-0505-4] [PMID: 32042099]

Zhao, H.; Gulesserian, S.; Ganesan, S.K.; Zeng, Z.; Ou, J.; Robles, V. Abstract 3853: Potential mechanisms for thrombocytopenia and neutropenia induced by antibody-drug conjugates. Cancer Res., 2016, 76, 3853-3853.

Chiorean, E.G.; LoRusso, P.; Strother, R.M.; Diamond, J.R.; Younger, A.; Messersmith, W.A.; Adriaens, L.; Liu, L.; Kao, R.J.; DiCioccio, A.T.; Kostic, A.; Leek, R.; Harris, A.; Jimeno, A. A phase I first-in-human study of enoticumab (REGN421), a fully human delta-like ligand 4 (Dll4) monoclonal antibody in patients with advanced solid tumors. Clin. Cancer Res., 2015, 21(12), 2695-2703.
[http://dx.doi.org/10.1158/1078-0432.CCR-14-2797] [PMID: 25724527]

Zhang, Y.; Li, D.; Jiang, Q.; Cao, S.; Sun, H.; Chai, Y.; Li, X.; Ren, T.; Yang, R.; Feng, F.; Li, B.A.; Zhao, Q. Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells. Cell Death Dis., 2018, 9(7), 743.
[http://dx.doi.org/10.1038/s41419-018-0804-6] [PMID: 29970890]

El-Khoueiry, A.B.; Desai, J.; Iyer, S.P.; Gadgeel, S.M.; Ramalingam, S.S.; Horn, L. A phase I study of AL101, a pan-NOTCH inhibitor, in patients (pts) with locally advanced or metastatic solid tumors. J. Clin. Oncol., 2018, 36(15), 2515-2515.
[http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.2515]

Habets, R.A.; de Bock, C.E.; Serneels, L.; Lodewijckx, I.; Verbeke, D.; Nittner, D.; Narlawar, R.; Demeyer, S.; Dooley, J.; Liston, A.; Taghon, T.; Cools, J.; de Strooper, B. Safe targeting of T cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibition. Sci. Transl. Med., 2019, 11(494)eaau6246
[http://dx.doi.org/10.1126/scitranslmed.aau6246] [PMID: 31142678]

Munchhof, M.J.; Li, Q.; Shavnya, A.; Borzillo, G.V.; Boyden, T.L.; Jones, C.S.; LaGreca, S.D.; Martinez-Alsina, L.; Patel, N.; Pelletier, K.; Reiter, L.A.; Robbins, M.D.; Tkalcevic, G.T. Discovery of PF-04449913, a potent and orally bioavailable inhibitor of smoothened. ACS Med. Chem. Lett., 2011, 3(2), 106-111.
[http://dx.doi.org/10.1021/ml2002423] [PMID: 24900436]

Pan, S.; Wu, X.; Jiang, J.; Gao, W.; Wan, Y.; Cheng, D.; Han, D.; Liu, J.; Englund, N.P.; Wang, Y.; Peukert, S.; Miller-Moslin, K.; Yuan, J.; Guo, R.; Matsumoto, M.; Vattay, A.; Jiang, Y.; Tsao, J.; Sun, F.; Pferdekamper, A.C.; Dodd, S.; Tuntland, T.; Maniara, W.; Kelleher, J.F., III; Yao, Y.M.; Warmuth, M.; Williams, J.; Dorsch, M. Discovery of NVP-LDE225, a potent and selective smoothened antagonist. ACS Med. Chem. Lett., 2010, 1(3), 130-134.
[http://dx.doi.org/10.1021/ml1000307] [PMID: 24900187]

Robarge, K.D.; Brunton, S.A.; Castanedo, G.M.; Cui, Y.; Dina, M.S.; Goldsmith, R.; Gould, S.E.; Guichert, O.; Gunzner, J.L.; Halladay, J.; Jia, W.; Khojasteh, C.; Koehler, M.F.; Kotkow, K.; La, H.; Lalonde, R.L.; Lau, K.; Lee, L.; Marshall, D.; Marsters, J.C., Jr; Murray, L.J.; Qian, C.; Rubin, L.L.; Salphati, L.; Stanley, M.S.; Stibbard, J.H.; Sutherlin, D.P.; Ubhayaker, S.; Wang, S.; Wong, S.; Xie, M. GDC-0449-a potent inhibitor of the hedgehog pathway. Bioorg. Med. Chem. Lett., 2009, 19(19), 5576-5581.
[http://dx.doi.org/10.1016/j.bmcl.2009.08.049] [PMID: 19716296]

Stanton, B.Z.; Peng, L.F.; Maloof, N.; Nakai, K.; Wang, X.; Duffner, J.L.; Taveras, K.M.; Hyman, J.M.; Lee, S.W.; Koehler, A.N.; Chen, J.K.; Fox, J.L.; Mandinova, A.; Schreiber, S.L. A small molecule that binds Hedgehog and blocks its signaling in human cells. Nat. Chem. Biol., 2009, 5(3), 154-156.
[http://dx.doi.org/10.1038/nchembio.142] [PMID: 19151731]

Ericson, J.; Morton, S.; Kawakami, A.; Roelink, H.; Jessell, T.M. Two critical periods of Sonic Hedgehog signaling required for the specification of motor neuron identity. Cell, 1996, 87(4), 661-673.
[http://dx.doi.org/10.1016/S0092-8674(00)81386-0] [PMID: 8929535]

Lauth, M.; Bergström, A.; Shimokawa, T.; Toftgård, R. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc. Natl. Acad. Sci. USA, 2007, 104(20), 8455-8460.
[http://dx.doi.org/10.1073/pnas.0609699104] [PMID: 17494766]

Hyman, J.M.; Firestone, A.J.; Heine, V.M.; Zhao, Y.; Ocasio, C.A.; Han, K.; Sun, M.; Rack, P.G.; Sinha, S.; Wu, J.J.; Solow-Cordero, D.E.; Jiang, J.; Rowitch, D.H.; Chen, J.K. Small-molecule inhibitors reveal multiple strategies for Hedgehog pathway blockade. Proc. Natl. Acad. Sci. USA, 2009, 106(33), 14132-14137.
[http://dx.doi.org/10.1073/pnas.0907134106] [PMID: 19666565]

Shapiro, G.I. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin. Cancer Res., 2004, 10(12 Pt 2), 4270s-4275s.
[http://dx.doi.org/10.1158/1078-0432.CCR-040020] [PMID: 15217973]

Cicenas, J.; Kalyan, K.; Sorokinas, A.; Stankunas, E.; Levy, J.; Meskinyte, I.; Stankevicius, V.; Kaupinis, A.; Valius, M. Roscovitine in cancer and other diseases. Ann. Transl. Med., 2015, 3(10), 135.
[PMID: 26207228]

Dey, A.; Wong, E.T.; Cheok, C.F.; Tergaonkar, V.; Lane, D.P. R-Roscovitine simultaneously targets both the p53 and NF-kappaB pathways and causes potentiation of apoptosis: implications in cancer therapy. Cell Death Differ., 2008, 15(2), 263-273.
[http://dx.doi.org/10.1038/sj.cdd.4402257] [PMID: 17975552]

Parry, D.; Guzi, T.; Shanahan, F.; Davis, N.; Prabhavalkar, D.; Wiswell, D.; Seghezzi, W.; Paruch, K.; Dwyer, M.P.; Doll, R.; Nomeir, A.; Windsor, W.; Fischmann, T.; Wang, Y.; Oft, M.; Chen, T.; Kirschmeier, P.; Lees, E.M. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol. Cancer Ther., 2010, 9(8), 2344-2353.
[http://dx.doi.org/10.1158/1535-7163.MCT-10-0324] [PMID: 20663931]

Feldmann, G.; Mishra, A.; Bisht, S.; Karikari, C.; Garrido-Laguna, I.; Rasheed, Z.; Ottenhof, N.A.; Dadon, T.; Alvarez, H.; Fendrich, V.; Rajeshkumar, N.V.; Matsui, W.; Brossart, P.; Hidalgo, M.; Bannerji, R.; Maitra, A.; Nelkin, B.D. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol. Ther., 2011, 12(7), 598-609.
[http://dx.doi.org/10.4161/cbt.12.7.16475] [PMID: 21768779]

Fry, D.W.; Harvey, P.J.; Keller, P.R.; Elliott, W.L.; Meade, M.; Trachet, E.; Albassam, M.; Zheng, X.; Leopold, W.R.; Pryer, N.K.; Toogood, P.L. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther., 2004, 3(11), 1427-1438.
[PMID: 15542782]

Hortobagyi, G.N.; Stemmer, S.M.; Burris, H.A.; Yap, Y.S.; Sonke, G.S.; Paluch-Shimon, S.; Campone, M.; Blackwell, K.L.; André, F.; Winer, E.P.; Janni, W.; Verma, S.; Conte, P.; Arteaga, C.L.; Cameron, D.A.; Petrakova, K.; Hart, L.L.; Villanueva, C.; Chan, A.; Jakobsen, E.; Nusch, A.; Burdaeva, O.; Grischke, E.M.; Alba, E.; Wist, E.; Marschner, N.; Favret, A.M.; Yardley, D.; Bachelot, T.; Tseng, L.M.; Blau, S.; Xuan, F.; Souami, F.; Miller, M.; Germa, C.; Hirawat, S.; O’Shaughnessy, J. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N. Engl. J. Med., 2016, 375(18), 1738-1748.
[http://dx.doi.org/10.1056/NEJMoa1609709] [PMID: 27717303]

Martin, J.M.; Goldstein, L.J. Profile of abemaciclib and its potential in the treatment of breast cancer. OncoTargets Ther., 2018, 11, 5253-5259.
[http://dx.doi.org/10.2147/OTT.S149245] [PMID: 30214230]

Canon, J.; Osgood, T.; Olson, S.H.; Saiki, A.Y.; Robertson, R.; Yu, D.; Eksterowicz, J.; Ye, Q.; Jin, L.; Chen, A.; Zhou, J.; Cordover, D.; Kaufman, S.; Kendall, R.; Oliner, J.D.; Coxon, A.; Radinsky, R. The MDM2 inhibitor AMG 232 demonstrates robust antitumor efficacy and potentiates the activity of p53-inducing cytotoxic agents. Mol. Cancer Ther., 2015, 14(3), 649-658.
[http://dx.doi.org/10.1158/1535-7163.MCT-14-0710] [PMID: 25567130]

Jafri, M.A.; Ansari, S.A.; Alqahtani, M.H.; Shay, J.W. Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies. Genome Med., 2016, 8(1), 69.
[http://dx.doi.org/10.1186/s13073-016-0324-x] [PMID: 27323951]

Guzi, T.J.; Paruch, K.; Dwyer, M.P.; Labroli, M.; Shanahan, F.; Davis, N.; Taricani, L.; Wiswell, D.; Seghezzi, W.; Penaflor, E.; Bhagwat, B.; Wang, W.; Gu, D.; Hsieh, Y.; Lee, S.; Liu, M.; Parry, D. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol. Cancer Ther., 2011, 10(4), 591-602.
[http://dx.doi.org/10.1158/1535-7163.MCT-10-0928] [PMID: 21321066]

Bi, S.; Wei, Q.; Zhao, Z.; Chen, L.; Wang, C.; Xie, S. Wee1 inhibitor AZD1775 effectively inhibits the malignant phenotypes of esophageal squamous cell carcinoma in vitro and in vivo. Front. Pharmacol., 2019, 10, 864.
[http://dx.doi.org/10.3389/fphar.2019.00864] [PMID: 31427973]

Davies, K.D.; Cable, P.L.A.; Garrus, J.E.; Sullivan, F.X.; von Carlowitz, I.; Huerou, Y.L.; Wallace, E.; Woessner, R.D.; Gross, S. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation. Cancer Biol. Ther., 2011, 12(9), 788-796.
[http://dx.doi.org/10.4161/cbt.12.9.17673] [PMID: 21892012]

Gumireddy, K.; Reddy, M.V.R.; Cosenza, S.C.; Boominathan, R.; Baker, S.J.; Papathi, N.; Jiang, J.; Holland, J.; Reddy, E.P. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell, 2005, 7(3), 275-286.
[http://dx.doi.org/10.1016/j.ccr.2005.02.009] [PMID: 15766665]

Abdelfatah, S.; Berg, A.; Huang, Q.; Yang, L.J.; Hamdoun, S.; Klinger, A.; Greten, H.J.; Fleischer, E.; Berg, T.; Wong, V.K.W.; Efferth, T. MCC1019, a selective inhibitor of the Polo-box domain of Polo-like kinase 1 as novel, potent anticancer candidate. Acta Pharm. Sin. B, 2019, 9(5), 1021-1034.
[http://dx.doi.org/10.1016/j.apsb.2019.02.001] [PMID: 31649851]

Moretti, L.; Niermann, K.; Schleicher, S.; Giacalone, N.J.; Varki, V.; Kim, K.W.; Kopsombut, P.; Jung, D.K.; Lu, B. MLN8054, a small molecule inhibitor of aurora kinase a, sensitizes androgen-resistant prostate cancer to radiation. Int. J. Radiat. Oncol. Biol. Phys., 2011, 80(4), 1189-1197.
[http://dx.doi.org/10.1016/j.ijrobp.2011.01.060] [PMID: 21514073]

Mayeux, R. Biomarkers: potential uses and limitations. NeuroRx, 2004, 1(2), 182-188.
[http://dx.doi.org/10.1602/neurorx.1.2.182] [PMID: 15717018]

Mehta, S.; Shelling, A.; Muthukaruppan, A.; Lasham, A.; Blenkiron, C.; Laking, G.; Print, C. Predictive and prognostic molecular markers for cancer medicine. Ther. Adv. Med. Oncol., 2010, 2(2), 125-148.
[http://dx.doi.org/10.1177/1758834009360519] [PMID: 21789130]

Couch, F.J.; Nathanson, K.L.; Offit, K. Two decades after BRCA: setting paradigms in personalized cancer care and prevention.Science (80-), 2014, 343(6178), 1466-1470.,

Taube, J.M.; Klein, A.; Brahmer, J.R.; Xu, H.; Pan, X.; Kim, J.H.; Chen, L.; Pardoll, D.M.; Topalian, S.L.; Anders, R.A. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res., 2014, 20(19), 5064-5074.
[http://dx.doi.org/10.1158/1078-0432.CCR-13-3271] [PMID: 24714771]

Brahmer, J.R.; Drake, C.G.; Wollner, I.; Powderly, J.D.; Picus, J.; Sharfman, W.H.; Stankevich, E.; Pons, A.; Salay, T.M.; McMiller, T.L.; Gilson, M.M.; Wang, C.; Selby, M.; Taube, J.M.; Anders, R.; Chen, L.; Korman, A.J.; Pardoll, D.M.; Lowy, I.; Topalian, S.L. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol., 2010, 28(19), 3167-3175.
[http://dx.doi.org/10.1200/JCO.2009.26.7609] [PMID: 20516446]

Marchetti, A.; Barberis, M.; Franco, R.; De Luca, G.; Pace, M.V.; Staibano, S.; Volante, M.; Buttitta, F.; Guerini-Rocco, E.; Righi, L.; D’antuono, T.; Scagliotti, G.V.; Pinto, C.; De Rosa, G.; Papotti, M. Multicenter comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) assays to test PD-L1 expression for NSCLC patients to be treated with immune checkpoint inhibitors. J. Thorac. Oncol., 2017, 12(11), 1654-1663.
[http://dx.doi.org/10.1016/j.jtho.2017.07.031] [PMID: 28818609]

Cheng, D.T.; Mitchell, T.N.; Zehir, A.; Shah, R.H.; Benayed, R.; Syed, A.; Chandramohan, R.; Liu, Z.Y.; Won, H.H.; Scott, S.N.; Brannon, A.R.; O’Reilly, C.; Sadowska, J.; Casanova, J.; Yannes, A.; Hechtman, J.F.; Yao, J.; Song, W.; Ross, D.S.; Oultache, A.; Dogan, S.; Borsu, L.; Hameed, M.; Nafa, K.; Arcila, M.E.; Ladanyi, M.; Berger, M.F. Memorial sloan kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J. Mol. Diagn., 2015, 17(3), 251-264.
[http://dx.doi.org/10.1016/j.jmoldx.2014.12.006] [PMID: 25801821]

Chan, T.A.; Yarchoan, M.; Jaffee, E.; Swanton, C.; Quezada, S.A.; Stenzinger, A.; Peters, S. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann. Oncol., 2019, 30(1), 44-56.
[http://dx.doi.org/10.1093/annonc/mdy495] [PMID: 30395155]

Imperiale, T.F.; Ransohoff, D.F.; Itzkowitz, S.H.; Levin, T.R.; Lavin, P.; Lidgard, G.P.; Ahlquist, D.A.; Berger, B.M. Multitarget stool DNA testing for colorectal-cancer screening. N. Engl. J. Med., 2014, 370(14), 1287-1297.
[http://dx.doi.org/10.1056/NEJMoa1311194] [PMID: 24645800]

Shapiro, J.A.; Bobo, J.K.; Church, T.R.; Rex, D.K.; Chovnick, G.; Thompson, T.D.; Zauber, A.G.; Lieberman, D.; Levin, T.R.; Joseph, D.A.; Nadel, M.R. A comparison of fecal immunochemical and high-sensitivity guaiac tests for colorectal cancer screening. Am. J. Gastroenterol., 2017, 112(11), 1728-1735.
[http://dx.doi.org/10.1038/ajg.2017.285] [PMID: 29016558]

Golan, T.; Hammel, P.; Reni, M.; Van Cutsem, E.; Macarulla, T.; Hall, M.J.; Park, J.O.; Hochhauser, D.; Arnold, D.; Oh, D.Y.; Reinacher-Schick, A.; Tortora, G.; Algül, H.; O’Reilly, E.M.; McGuinness, D.; Cui, K.Y.; Schlienger, K.; Locker, G.Y.; Kindler, H.L. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N. Engl. J. Med., 2019, 381(4), 317-327.
[http://dx.doi.org/10.1056/NEJMoa1903387] [PMID: 31157963]

Gunderson, C.C.; Moore, K.N. BRACAnalysis CDx as a companion diagnostic tool for Lynparza. Expert Rev. Mol. Diagn., 2015, 15(9), 1111-1116.
[http://dx.doi.org/10.1586/14737159.2015.1078238] [PMID: 26292709]

Gittelman, M.C.; Hertzman, B.; Bailen, J.; Williams, T.; Koziol, I.; Henderson, R.J.; Efros, M.; Bidair, M.; Ward, J.F. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. J. Urol., 2013, 190(1), 64-69.
[http://dx.doi.org/10.1016/j.juro.2013.02.018] [PMID: 23416644]

Alunni-Fabbroni, M.; Rönsch, K.; Huber, T.; Cyran, C.C.; Seidensticker, M.; Mayerle, J.; Pech, M.; Basu, B.; Verslype, C.; Benckert, J.; Malfertheiner, P.; Ricke, J. Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial. J. Transl. Med., 2019, 17(1), 328.
[http://dx.doi.org/10.1186/s12967-019-2079-9] [PMID: 31570105]

Newman, A.M.; Bratman, S.V.; To, J.; Wynne, J.F.; Eclov, N.C.W.; Modlin, L.A.; Liu, C.L.; Neal, J.W.; Wakelee, H.A.; Merritt, R.E.; Shrager, J.B.; Loo, B.W., Jr; Alizadeh, A.A.; Diehn, M. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat. Med., 2014, 20(5), 548-554.
[http://dx.doi.org/10.1038/nm.3519] [PMID: 24705333]

Thakur, B.K.; Zhang, H.; Becker, A.; Matei, I.; Huang, Y.; Costa-Silva, B.; Zheng, Y.; Hoshino, A.; Brazier, H.; Xiang, J.; Williams, C.; Rodriguez-Barrueco, R.; Silva, J.M.; Zhang, W.; Hearn, S.; Elemento, O.; Paknejad, N.; Manova-Todorova, K.; Welte, K.; Bromberg, J.; Peinado, H.; Lyden, D. Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res., 2014, 24(6), 766-769.
[http://dx.doi.org/10.1038/cr.2014.44] [PMID: 24710597]

Wang, L.; Li, Y.; Guan, X.; Zhao, J.; Shen, L.; Liu, J. Exosomal double-stranded DNA as a biomarker for the diagnosis and preoperative assessment of pheochromocytoma and paraganglioma. Mol. Cancer, 2018, 17(1), 128.
[http://dx.doi.org/10.1186/s12943-018-0876-z] [PMID: 30139385]

Xi, X.; Li, T.; Huang, Y.; Sun, J.; Zhu, Y.; Yang, Y.; Lu, Z.J. RNA biomarkers: Frontier of precision medicine for cancer. Noncoding RNA, 2017, 3(1), 9.
[http://dx.doi.org/10.3390/ncrna3010009] [PMID: 29657281]

Bachmayr-Heyda, A.; Reiner, A.T.; Auer, K.; Sukhbaatar, N.; Aust, S.; Bachleitner-Hofmann, T.; Mesteri, I.; Grunt, T.W.; Zeillinger, R.; Pils, D. Correlation of circular RNA abundance with proliferation-exemplified with colorectal and ovarian cancer, idiopathic lung fibrosis, and normal human tissues. Sci. Rep., 2015, 5(1), 8057.
[http://dx.doi.org/10.1038/srep08057] [PMID: 25624062]

Li, P.; Chen, S.; Chen, H.; Mo, X.; Li, T.; Shao, Y.; Xiao, B.; Guo, J. Using circular RNA as a novel type of biomarker in the screening of gastric cancer. Clin. Chim. Acta, 2015, 444, 132-136.
[http://dx.doi.org/10.1016/j.cca.2015.02.018] [PMID: 25689795]

Zhang, H.D.; Jiang, L.H.; Sun, D.W.; Hou, J.C.; Ji, Z.L. CircRNA: a novel type of biomarker for cancer. Breast Cancer, 2018, 25(1), 1-7.
[http://dx.doi.org/10.1007/s12282-017-0793-9] [PMID: 28721656]

Chen, B.; Huang, S. Circular RNA: an emerging non-coding RNA as a regulator and biomarker in cancer. Cancer Lett., 2018, 418, 41-50.
[http://dx.doi.org/10.1016/j.canlet.2018.01.011] [PMID: 29330104]

Ogata-Kawata, H.; Izumiya, M.; Kurioka, D.; Honma, Y.; Yamada, Y.; Furuta, K.; Gunji, T.; Ohta, H.; Okamoto, H.; Sonoda, H.; Watanabe, M.; Nakagama, H.; Yokota, J.; Kohno, T.; Tsuchiya, N. Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS One, 2014, 9(4)e92921
[http://dx.doi.org/10.1371/journal.pone.0092921] [PMID: 24705249]

Taylor, D.D.; Gercel-Taylor, C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol., 2008, 110(1), 13-21.
[http://dx.doi.org/10.1016/j.ygyno.2008.04.033] [PMID: 18589210]

Iorio, M.V.; Croce, C.M. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol. Med., 2012, 4(3), 143-159.
[http://dx.doi.org/10.1002/emmm.201100209] [PMID: 22351564]

Schwarzenbach, H.; Nishida, N.; Calin, G.A.; Pantel, K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat. Rev. Clin. Oncol., 2014, 11(3), 145-156.
[http://dx.doi.org/10.1038/nrclinonc.2014.5] [PMID: 24492836]

Hamam, R.; Ali, A.M.; Alsaleh, K.A.; Kassem, M.; Alfayez, M.; Aldahmash, A.; Alajez, N.M. microRNA expression profiling on individual breast cancer patients identifies novel panel of circulating microRNA for early detection. Sci. Rep., 2016, 6(1), 25997.
[http://dx.doi.org/10.1038/srep25997] [PMID: 27180809]

Condrat, C.E.; Thompson, D.C.; Barbu, M.G.; Bugnar, O.L.; Boboc, A.; Cretoiu, D.; Suciu, N.; Cretoiu, S.M.; Voinea, S.C. miRNAs as biomarkers in disease: latest findings regarding their role in diagnosis and prognosis. Cells, 2020, 9(2), 276.
[http://dx.doi.org/10.3390/cells9020276] [PMID: 31979244]

Zhang, H.; Mao, F.; Shen, T.; Luo, Q.; Ding, Z.; Qian, L.; Huang, J. Plasma miR-145, miR-20a, miR-21 and miR-223 as novel biomarkers for screening early-stage non-small cell lung cancer. Oncol. Lett., 2017, 13(2), 669-676.
[http://dx.doi.org/10.3892/ol.2016.5462] [PMID: 28356944]

Shao, Y.; Chen, L.; Lu, R.; Zhang, X.; Xiao, B.; Ye, G.; Guo, J. Decreased expression of hsa_circ_0001895 in human gastric cancer and its clinical significances. Tumour Biol., 2017, 39(4)1010428317699125
[http://dx.doi.org/10.1177/1010428317699125] [PMID: 28443463]

Chen, S.; Li, T.; Zhao, Q.; Xiao, B.; Guo, J. Using circular RNA hsa_circ_0000190 as a new biomarker in the diagnosis of gastric cancer. Clin. Chim. Acta, 2017, 466, 167-171.
[http://dx.doi.org/10.1016/j.cca.2017.01.025] [PMID: 28130019]

Peng, W.; Zhu, J.; Liu, D.; Qian, P.; Zhang, Q.; Li, H. Clinical value of piR-36026 and piR-651 in esophageal squamous cell carcinoma. J. Clin. Oncol., 2020, 38(15), e15265-e15265.
[http://dx.doi.org/10.1200/JCO.2020.38.15_suppl.e15265]

Cordeiro, A.; Navarro, A.; Gaya, A.; Díaz-Beyá, M.; Gonzalez-Farré, B.; Castellano, J.J.; Fuster, D.; Martínez, C.; Martínez, A.; Monzó, M. PiwiRNA-651 as marker of treatment response and survival in classical Hodgkin lymphoma. Oncotarget, 2016, 7(29), 46002-46013.
[http://dx.doi.org/10.18632/oncotarget.10015] [PMID: 27329591]

Yang, Z.; Zhou, L.; Wu, L.M.; Lai, M.C.; Xie, H.Y.; Zhang, F.; Zheng, S.S. Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. Ann. Surg. Oncol., 2011, 18(5), 1243-1250.
[http://dx.doi.org/10.1245/s10434-011-1581-y] [PMID: 21327457]

Geng, Y.J.; Xie, S.L.; Li, Q.; Ma, J.; Wang, G.Y. Large intervening non-coding RNA HOTAIR is associated with hepatocellular carcinoma progression. J. Int. Med. Res., 2011, 39(6), 2119-2128.
[http://dx.doi.org/10.1177/147323001103900608] [PMID: 22289527]

Kogo, R.; Shimamura, T.; Mimori, K.; Kawahara, K.; Imoto, S.; Sudo, T.; Tanaka, F.; Shibata, K.; Suzuki, A.; Komune, S.; Miyano, S.; Mori, M. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res., 2011, 71(20), 6320-6326.
[http://dx.doi.org/10.1158/0008-5472.CAN-11-1021] [PMID: 21862635]

Kim, K.; Jutooru, I.; Chadalapaka, G.; Johnson, G.; Frank, J.; Burghardt, R.; Kim, S.; Safe, S. HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene, 2013, 32(13), 1616-1625.
[http://dx.doi.org/10.1038/onc.2012.193] [PMID: 22614017]

Sørensen, K.P.; Thomassen, M.; Tan, Q.; Bak, M.; Cold, S.; Burton, M.; Larsen, M.J.; Kruse, T.A. Long non-coding RNA HOTAIR is an independent prognostic marker of metastasis in estrogen receptor-positive primary breast cancer. Breast Cancer Res. Treat., 2013, 142(3), 529-536.
[http://dx.doi.org/10.1007/s10549-013-2776-7] [PMID: 24258260]

Pellegrini, K.L.; Sanda, M.G.; Moreno, C.S. RNA biomarkers to facilitate the identification of aggressive prostate cancer. Mol. Aspects Med., 2015, 45, 37-46.
[http://dx.doi.org/10.1016/j.mam.2015.05.003] [PMID: 26022941]

Liu, Y.; Zong, Z.H.; Guan, X.; Wang, L.L.; Zhao, Y. The role of long non-coding RNA PCA3 in epithelial ovarian carcinoma tumorigenesis and progression. Gene, 2017, 633, 42-47.
[http://dx.doi.org/10.1016/j.gene.2017.08.027] [PMID: 28864116]

Lemos, A.E.G.; Matos, A.D.R.; Ferreira, L.B.; Gimba, E.R.P. The long non-coding RNA PCA3: an update of its functions and clinical applications as a biomarker in prostate cancer. Oncotarget, 2019, 10(61), 6589-6603.
[http://dx.doi.org/10.18632/oncotarget.27284] [PMID: 31762940]

Pu, M.; Messer, K.; Davies, S.R.; Vickery, T.L.; Pittman, E.; Parker, B.A.; Ellis, M.J.; Flatt, S.W.; Marinac, C.R.; Nelson, S.H.; Mardis, E.R.; Pierce, J.P.; Natarajan, L. Research-based PAM50 signature and long-term breast cancer survival. Breast Cancer Res. Treat., 2020, 179(1), 197-206.
[http://dx.doi.org/10.1007/s10549-019-05446-y] [PMID: 31542876]

Ochoa, S.; de Anda-Jáuregui, G.; Hernández-Lemus, E. Multi-omic regulation of the PAM50 gene signature in breast cancer molecular subtypes. Front. Oncol., 2020, 10, 845.
[http://dx.doi.org/10.3389/fonc.2020.00845] [PMID: 32528899]

March-Villalba, J.A.; Martínez-Jabaloyas, J.M.; Herrero, M.J.; Santamaria, J.; Aliño, S.F.; Dasí, F. Cell-free circulating plasma hTERT mRNA is a useful marker for prostate cancer diagnosis and is associated with poor prognosis tumor characteristics. PLoS One, 2012, 7(8)e43470
[http://dx.doi.org/10.1371/journal.pone.0043470] [PMID: 22916267]

Liao, J.; Yu, L.; Mei, Y.; Guarnera, M.; Shen, J.; Li, R.; Liu, Z.; Jiang, F. Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer. Mol. Cancer, 2010, 9(1), 198.
[http://dx.doi.org/10.1186/1476-4598-9-198] [PMID: 20663213]

Mourksi, N-E-H.; Morin, C.; Fenouil, T.; Diaz, J-J.; Marcel, V. snoRNAs offer novel insight and promising perspectives for lung cancer understanding and management. Cells, 2020, 9(3), 541.
[http://dx.doi.org/10.3390/cells9030541] [PMID: 32111002]

Hwang, J.H.; Voortman, J.; Giovannetti, E.; Steinberg, S.M.; Leon, L.G.; Kim, Y.T.; Funel, N.; Park, J.K.; Kim, M.A.; Kang, G.H.; Kim, S.W.; Del Chiaro, M.; Peters, G.J.; Giaccone, G. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One, 2010, 5(5)e10630
[http://dx.doi.org/10.1371/journal.pone.0010630] [PMID: 20498843]

Teplyuk, N.M.; Mollenhauer, B.; Gabriely, G.; Giese, A.; Kim, E.; Smolsky, M.; Kim, R.Y.; Saria, M.G.; Pastorino, S.; Kesari, S.; Krichevsky, A.M. MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro-oncol., 2012, 14(6), 689-700.
[http://dx.doi.org/10.1093/neuonc/nos074] [PMID: 22492962]

Wei, J.; Gao, W.; Zhu, C.J.; Liu, Y.Q.; Mei, Z.; Cheng, T.; Shu, Y.Q. Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin. J. Cancer, 2011, 30(6), 407-414.
[http://dx.doi.org/10.5732/cjc.010.10522] [PMID: 21627863]

Wu, J.; Li, G.; Wang, Z.; Yao, Y.; Chen, R.; Pu, X.; Wang, J. Circulating MicroRNA-21 is a potential diagnostic biomarker in gastric cancer. Dis. Markers, 2015, 2015435656
[http://dx.doi.org/10.1155/2015/435656] [PMID: 26063956]

Simonian, M.; Mosallayi, M.; Mirzaei, H. Circulating miR-21 as novel biomarker in gastric cancer: diagnostic and prognostic biomarker. J. Cancer Res. Ther., 2018, 14(2), 475.
[PMID: 29516946]

Liu, G.H.; Zhou, Z.G.; Chen, R.; Wang, M.J.; Zhou, B.; Li, Y.; Sun, X.F. Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of colorectal cancer. Tumour Biol., 2013, 34(4), 2175-2181.
[http://dx.doi.org/10.1007/s13277-013-0753-8] [PMID: 23625654]

Staff, A.C. An introduction to gene therapy and its potential prenatal use. Acta Obstet. Gynecol. Scand., 2001, 80(6), 485-491.
[PMID: 11380282]

Cai, M.; Yang, Y. Targeted genome editing tools for disease modeling and gene therapy. Curr. Gene Ther., 2014, 14(1), 2-9.
[http://dx.doi.org/10.2174/156652321402140318165450] [PMID: 24665839]

Gaj, T.; Sirk, S.J.; Shui, S.L.; Liu, J. Genome-editing technologies: principles and applications. Cold Spring Harb. Perspect. Biol., 2016, 8(12)a023754
[http://dx.doi.org/10.1101/cshperspect.a023754] [PMID: 27908936]

Li, H.; Yang, Y.; Hong, W.; Huang, M.; Wu, M.; Zhao, X. Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduct. Target. Ther., 2020, 5(1), 1-23.
[http://dx.doi.org/10.1038/s41392-019-0089-y] [PMID: 32296011]

Gaj, T.; Gersbach, C.A.; Barbas, C.F., III ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol., 2013, 31(7), 397-405.
[http://dx.doi.org/10.1016/j.tibtech.2013.04.004] [PMID: 23664777]

Kim, H.; Kim, J.S. A guide to genome engineering with programmable nucleases. Nat. Rev. Genet., 2014, 15(5), 321-334.
[http://dx.doi.org/10.1038/nrg3686] [PMID: 24690881]

Franic, D.; Dobrinic, P.; Korac, P. Key achievements in gene therapy development and its promising progress with gene editing tools (ZFN, TALEN, CRISPR/Cas9). Mol. Exp. Biol. Med., 2019, 2(1).,

Shuvalov, O.; Petukhov, A.; Daks, A.; Fedorova, O.; Ermakov, A.; Melino, G.; Barlev, N.A. Current genome editing tools in gene therapy: new approaches to treat cancer. Curr. Gene Ther., 2015, 15(5), 511-529.
[http://dx.doi.org/10.2174/1566523215666150818110241] [PMID: 26282844]

Qasim, W.; Amrolia, P.J.; Samarasinghe, S.; Ghorashian, S.; Zhan, H.; Stafford, S. First clinical application of talen engineered universal CAR19 T cells in B-ALL. Blood, 2015, 126(23), 2046-2046.
[http://dx.doi.org/10.1182/blood.V126.23.2046.2046]

Lam, P.; Khan, G.; Stripecke, R.; Hui, K.M.; Kasahara, N.; Peng, K.W.; Guinn, B.A. The innovative evolution of cancer gene and cellular therapies. Cancer Gene Ther., 2013, 20(3), 141-149.
[http://dx.doi.org/10.1038/cgt.2012.93] [PMID: 23370333]

Salmikangas, P.; Kinsella, N.; Chamberlain, P. Chimeric Antigen Receptor T-Cells (CAR T-Cells) for cancer immunotherapy - moving target for industry? Pharm. Res., 2018, 35(8), 152.
[http://dx.doi.org/10.1007/s11095-018-2436-z] [PMID: 29855723]

Papadouli, I.; Mueller-Berghaus, J.; Beuneu, C.; Ali, S.; Hofner, B.; Petavy, F.; Tzogani, K.; Miermont, A.; Norga, K.; Kholmanskikh, O.; Leest, T.; Schuessler-Lenz, M.; Salmonson, T.; Gisselbrecht, C.; Garcia, J.L.; Pignatti, F. EMA review of axicabtagene ciloleucel (Yescarta) for the treatment of diffuse large B-cell lymphoma. Oncologist, 2020, 25(10), 894-902.
[http://dx.doi.org/10.1634/theoncologist.2019-0646] [PMID: 32339368]

O’Leary, M.C.; Lu, X.; Huang, Y.; Lin, X.; Mahmood, I.; Przepiorka, D.; Gavin, D.; Lee, S.; Liu, K.; George, B.; Bryan, W.; Theoret, M.R.; Pazdur, R. FDA Approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory b-cell precursor acute lymphoblastic leukemia. Clin. Cancer Res., 2019, 25(4), 1142-1146.
[http://dx.doi.org/10.1158/1078-0432.CCR-18-2035] [PMID: 30309857]

Prasad, V. Immunotherapy: tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers. Nat. Rev. Clin. Oncol., 2018, 15(1), 11-12.
[http://dx.doi.org/10.1038/nrclinonc.2017.156] [PMID: 28975930]

Maude, S.L.; Laetsch, T.W.; Buechner, J.; Rives, S.; Boyer, M.; Bittencourt, H.; Bader, P.; Verneris, M.R.; Stefanski, H.E.; Myers, G.D.; Qayed, M.; De Moerloose, B.; Hiramatsu, H.; Schlis, K.; Davis, K.L.; Martin, P.L.; Nemecek, E.R.; Yanik, G.A.; Peters, C.; Baruchel, A.; Boissel, N.; Mechinaud, F.; Balduzzi, A.; Krueger, J.; June, C.H.; Levine, B.L.; Wood, P.; Taran, T.; Leung, M.; Mueller, K.T.; Zhang, Y.; Sen, K.; Lebwohl, D.; Pulsipher, M.A.; Grupp, S.A. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med., 2018, 378(5), 439-448.
[http://dx.doi.org/10.1056/NEJMoa1709866] [PMID: 29385370]

Seif, M.; Einsele, H.; Löffler, J. CAR T cells beyond cancer: hope for immunomodulatory therapy of infectious diseases. Front. Immunol., 2019, 10, 2711.
[http://dx.doi.org/10.3389/fimmu.2019.02711] [PMID: 31824500]

Liu, D. CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy. J. Hematol. Oncol., 2019, 12(1), 113.
[http://dx.doi.org/10.1186/s13045-019-0819-1] [PMID: 31703740]

Ribatti, D. The concept of immune surveillance against tumors. The first theories. Oncotarget, 2017, 8(4), 7175-7180.
[http://dx.doi.org/10.18632/oncotarget.12739] [PMID: 27764780]

Khalil, D.N.; Smith, E.L.; Brentjens, R.J.; Wolchok, J.D. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat. Rev. Clin. Oncol., 2016, 13(5), 273-290.
[http://dx.doi.org/10.1038/nrclinonc.2016.25] [PMID: 26977780]

Lesokhin, A.M.; Callahan, M.K.; Postow, M.A.; Wolchok, J.D. On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation.Sci. Transl. Med., 2015, 7(280), 280sr1-280sr1.,

Chen, D.S.; Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity, 2013, 39(1), 1-10.
[http://dx.doi.org/10.1016/j.immuni.2013.07.012] [PMID: 23890059]

Rossi, J.F.; Céballos, P.; Lu, Z.Y. Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells. Cancer Commun (Lond), 2019, 39(1), 34.
[http://dx.doi.org/10.1186/s40880-019-0379-3] [PMID: 31200766]

Lee, J.K.; Priceman, S.J. Precision Medicine-Enabled Cancer Immunotherapy.Cancer Treat. Res., 2019, 178, 189-205;
[http://dx.doi.org/10.1007/978-3-030-16391-4_7]

Sul, J.; Blumenthal, G.M.; Jiang, X.; He, K.; Keegan, P.; Pazdur, R. FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1. Oncologist, 2016, 21(5), 643-650.
[http://dx.doi.org/10.1634/theoncologist.2015-0498] [PMID: 27026676]

Pai-Scherf, L.; Blumenthal, G.M.; Li, H.; Subramaniam, S.; Mishra-Kalyani, P.S.; He, K.; Zhao, H.; Yu, J.; Paciga, M.; Goldberg, K.B.; McKee, A.E.; Keegan, P.; Pazdur, R. FDA approval summary: pembrolizumab for treatment of metastatic non-small cell lung cancer: first-line therapy and beyond. Oncologist, 2017, 22(11), 1392-1399.
[http://dx.doi.org/10.1634/theoncologist.2017-0078] [PMID: 28835513]

Lim, S.H.; Sun, J.M.; Lee, S.H.; Ahn, J.S.; Park, K.; Ahn, M.J. Pembrolizumab for the treatment of non-small cell lung cancer. Expert Opin. Biol. Ther., 2016, 16(3), 397-406.
[http://dx.doi.org/10.1517/14712598.2016.1145652] [PMID: 26800463]

Chuk, M.K.; Chang, J.T.; Theoret, M.R.; Sampene, E.; He, K.; Weis, S.L.; Helms, W.S.; Jin, R.; Li, H.; Yu, J.; Zhao, H.; Zhao, L.; Paciga, M.; Schmiel, D.; Rawat, R.; Keegan, P.; Pazdur, R. FDA approval summary: accelerated approval of pembrolizumab for second-line treatment of metastatic melanoma. Clin. Cancer Res., 2017, 23(19), 5666-5670.
[http://dx.doi.org/10.1158/1078-0432.CCR-16-0663] [PMID: 28235882]

Fashoyin-Aje, L.; Donoghue, M.; Chen, H.; He, K.; Veeraraghavan, J.; Goldberg, K.B.; Keegan, P.; McKee, A.E.; Pazdur, R. FDA approval summary: pembrolizumab for recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing PD-L1. Oncologist, 2019, 24(1), 103-109.
[http://dx.doi.org/10.1634/theoncologist.2018-0221] [PMID: 30120163]

Poole, R.M.; Vaidya, A. Ramucirumab: first global approval. Drugs, 2014, 74(9), 1047-1058.
[http://dx.doi.org/10.1007/s40265-014-0244-2] [PMID: 24916147]

Larkins, E.; Blumenthal, G.M.; Yuan, W.; He, K.; Sridhara, R.; Subramaniam, S.; Zhao, H.; Liu, C.; Yu, J.; Goldberg, K.B.; McKee, A.E.; Keegan, P.; Pazdur, R. FDA approval summary: pembrolizumab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy. Oncologist, 2017, 22(7), 873-878.
[http://dx.doi.org/10.1634/theoncologist.2016-0496] [PMID: 28533473]

Kazandjian, D.; Suzman, D.L.; Blumenthal, G.; Mushti, S.; He, K.; Libeg, M.; Keegan, P.; Pazdur, R. FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist, 2016, 21(5), 634-642.
[http://dx.doi.org/10.1634/theoncologist.2015-0507] [PMID: 26984449]

Raedler, L.A. Opdivo (nivolumab): second PD-1 inhibitor receives FDA approval for unresectable or metastatic melanoma. Am. Health Drug Benefits, 2015, 8, 180-183.

Le, D.T.; Durham, J.N.; Smith, K.N.; Wang, H.; Bartlett, B.R.; Aulakh, L.K. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science (80-), 2017, 8(Spec Feature), 180.,

Ning, Y.M.; Suzman, D.; Maher, V.E.; Zhang, L.; Tang, S.; Ricks, T.; Palmby, T.; Fu, W.; Liu, Q.; Goldberg, K.B.; Kim, G.; Pazdur, R. FDA approval summary: atezolizumab for the treatment of patients with progressive advanced urothelial carcinoma after platinum-containing chemotherapy. Oncologist, 2017, 22(6), 743-749.
[http://dx.doi.org/10.1634/theoncologist.2017-0087] [PMID: 28424325]

Weinstock, C.; Khozin, S.; Suzman, D.; Zhang, L.; Tang, S.; Wahby, S.; Goldberg, K.B.; Kim, G.; Pazdur, R.U.S. Food and Drug Administration approval summary: atezolizumab for metastatic non-small cell lung cancer. Clin. Cancer Res., 2017, 23(16), 4534-4539.
[http://dx.doi.org/10.1158/1078-0432.CCR-17-0540] [PMID: 28611199]

Kim, E.S. Avelumab: first global approval. Drugs, 2017, 77(8), 929-937.
[http://dx.doi.org/10.1007/s40265-017-0749-6] [PMID: 28456944]

Sambi, M.; Bagheri, L.; Szewczuk, M.R. Current challenges in cancer immunotherapy: multimodal approaches to improve efficacy and patient response rates. J. Oncol., 2019, 20194508794
[http://dx.doi.org/10.1155/2019/4508794] [PMID: 30941175]

Klemen, N.D.; Wang, M.; Feingold, P.L.; Cooper, K.; Pavri, S.N.; Han, D.; Detterbeck, F.C.; Boffa, D.J.; Khan, S.A.; Olino, K.; Clune, J.; Ariyan, S.; Salem, R.R.; Weiss, S.A.; Kluger, H.M.; Sznol, M.; Cha, C. Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma. J. Immunother. Cancer, 2019, 7(1), 196.
[http://dx.doi.org/10.1186/s40425-019-0672-3] [PMID: 31340861]

Qin, S.; Xu, L.; Yi, M.; Yu, S.; Wu, K.; Luo, S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol. Cancer, 2019, 18(1), 155.
[http://dx.doi.org/10.1186/s12943-019-1091-2] [PMID: 31690319]

Deng, R.; Zuo, C.; Li, Y.; Xue, B.; Xun, Z.; Guo, Y.; Wang, X.; Xu, Y.; Tian, R.; Chen, S.; Liu, Q.; Chen, J.; Wang, J.; Huang, X.; Li, H.; Guo, M.; Wang, X.; Yang, M.; Wu, Z.; Wang, J.; Ma, J.; Hu, J.; Li, G.; Tang, S.; Tu, Z.; Ji, H.; Zhu, H. The innate immune effector ISG12a promotes cancer immunity by suppressing the canonical Wnt/β-catenin signaling pathway. Cell. Mol. Immunol., 2020, 17(11), 1163-1179.
[http://dx.doi.org/10.1038/s41423-020-00549-9] [PMID: 32963356]

Higano, C.S.; Small, E.J.; Schellhammer, P.; Yasothan, U.; Gubernick, S.; Kirkpatrick, P. Sipuleucel-T. Nat. Rev. Drug Discov., 2010, 9(7), 513-514.

Gulley, J.L.; Mulders, P.; Albers, P.; Banchereau, J.; Bolla, M.; Pantel, K.; Powles, T. Perspectives on sipuleucel-T: its role in the prostate cancer treatment paradigm. OncoImmunology, 2015, 5(4)e1107698
[http://dx.doi.org/10.1080/2162402X.2015.1107698] [PMID: 27141392]

Kantoff, P.W.; Higano, C.S.; Shore, N.D.; Berger, E.R.; Small, E.J.; Penson, D.F.; Redfern, C.H.; Ferrari, A.C.; Dreicer, R.; Sims, R.B.; Xu, Y.; Frohlich, M.W.; Schellhammer, P.F. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med., 2010, 363(5), 411-422.
[http://dx.doi.org/10.1056/NEJMoa1001294] [PMID: 20818862]

Rehman, H.; Silk, A.W.; Kane, M.P.; Kaufman, H.L. Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. J. Immunother. Cancer, 2016, 4(1), 53.
[http://dx.doi.org/10.1186/s40425-016-0158-5] [PMID: 27660707]

Higano, C.S.; Corman, J.M.; Smith, D.C.; Centeno, A.S.; Steidle, C.P.; Gittleman, M.; Simons, J.W.; Sacks, N.; Aimi, J.; Small, E.J. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer, 2008, 113(5), 975-984.
[http://dx.doi.org/10.1002/cncr.23669] [PMID: 18646045]

Geary, S.M.; Salem, A.K. Prostate cancer vaccines: update on clinical development. OncoImmunology, 2013, 2(5)e24523
[http://dx.doi.org/10.4161/onci.24523] [PMID: 23762812]

Zhang, Q.; Ping, J.; Huang, Z.; Zhang, X.; Zhou, J.; Wang, G.; Liu, S.; Ma, J. CAR-T cell therapy in cancer: tribulations and road ahead. J. Immunol. Res., 2020, 20201924379
[http://dx.doi.org/10.1155/2020/1924379] [PMID: 32411789]

Morgan, D.A.; Ruscetti, F.W.; Gallo, R. Selective in vitro growth of T lymphocytes from normal human bone marrows.Science (80-), 1976, 193(4257), 1007-1008.,
[http://dx.doi.org/10.1126/science.181845]

Stevanović, S.; Helman, S.R.; Wunderlich, J.R.; Langhan, M.M.; Doran, S.L.; Kwong, M.L.M.; Somerville, R.P.T.; Klebanoff, C.A.; Kammula, U.S.; Sherry, R.M.; Yang, J.C.; Rosenberg, S.A.; Hinrichs, C.S. A Phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers. Clin. Cancer Res., 2019, 25(5), 1486-1493.
[http://dx.doi.org/10.1158/1078-0432.CCR-18-2722] [PMID: 30518633]

Kim, R.; Coppola, D.; Wang, E.; Chang, Y.D.; Kim, Y.; Anaya, D.; Kim, D.W. Prognostic value of CD8CD45RO tumor infiltrating lymphocytes in patients with extrahepatic cholangiocarcinoma. Oncotarget, 2018, 9(34), 23366-23372.
[http://dx.doi.org/10.18632/oncotarget.25163] [PMID: 29805739]

Ali, S.; Kjeken, R.; Niederlaender, C.; Markey, G.; Saunders, T.S.; Opsata, M.; Moltu, K.; Bremnes, B.; Grønevik, E.; Muusse, M.; Håkonsen, G.D.; Skibeli, V.; Kalland, M.E.; Wang, I.; Buajordet, I.; Urbaniak, A.; Johnston, J.; Rantell, K.; Kerwash, E.; Schuessler-Lenz, M.; Salmonson, T.; Bergh, J.; Gisselbrecht, C.; Tzogani, K.; Papadouli, I.; Pignatti, F. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the treatment of acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Oncologist, 2020, 25(2), e321-e327.
[http://dx.doi.org/10.1634/theoncologist.2019-0233] [PMID: 32043764]

Halford, Z.; Anderson, M.K.; Bennett, L.L.; Moody, J. Tisagenlecleucel in acute lymphoblastic leukemia: a review of the literature and practical considerations. Ann. Pharmacother., 2021, 55(4), 466-479.
[http://dx.doi.org/10.1177/1060028020948165] [PMID: 32762363]

Neelapu, S.S.; Locke, F.L.; Bartlett, N.L.; Lekakis, L.J.; Miklos, D.B.; Jacobson, C.A.; Braunschweig, I.; Oluwole, O.O.; Siddiqi, T.; Lin, Y.; Timmerman, J.M.; Stiff, P.J.; Friedberg, J.W.; Flinn, I.W.; Goy, A.; Hill, B.T.; Smith, M.R.; Deol, A.; Farooq, U.; McSweeney, P.; Munoz, J.; Avivi, I.; Castro, J.E.; Westin, J.R.; Chavez, J.C.; Ghobadi, A.; Komanduri, K.V.; Levy, R.; Jacobsen, E.D.; Witzig, T.E.; Reagan, P.; Bot, A.; Rossi, J.; Navale, L.; Jiang, Y.; Aycock, J.; Elias, M.; Chang, D.; Wiezorek, J.; Go, W.Y. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma. N. Engl. J. Med., 2017, 377(26), 2531-2544.
[http://dx.doi.org/10.1056/NEJMoa1707447] [PMID: 29226797]

Jacobson, C.A.; Farooq, U.; Ghobadi, A. Axicabtagene ciloleucel, an anti-cd19 chimeric antigen receptor T-Cell therapy for relapsed or refractory large B-cell lymphoma: practical implications for the community oncologist. Oncologist, 2020, 25(1), e138-e146.
[http://dx.doi.org/10.1634/theoncologist.2019-0395] [PMID: 31585984]

Rajabi, M.; Mousa, S.A. The role of angiogenesis in cancer treatment. Biomedicines, 2017, 5(2), 34.
[http://dx.doi.org/10.3390/biomedicines5020034] [PMID: 28635679]

Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell, 2000, 100(1), 57-70.
[http://dx.doi.org/10.1016/S0092-8674(00)81683-9] [PMID: 10647931]

Kobayashi, K.; Maeda, K.; Takefuji, M.; Kikuchi, R.; Morishita, Y.; Hirashima, M.; Murohara, T. Dynamics of angiogenesis in ischemic areas of the infarcted heart. Sci. Rep., 2017, 7(1), 7156.
[http://dx.doi.org/10.1038/s41598-017-07524-x] [PMID: 28769049]

Seto, S-W.; Chang, D.; Jenkins, A.; Bensoussan, A.; Kiat, H. Angiogenesis in ischemic stroke and angiogenic effects of chinese herbal medicine. J. Clin. Med., 2016, 5(6), 56.
[http://dx.doi.org/10.3390/jcm5060056] [PMID: 27275837]

Szekanecz, Z.; Koch, A.E. Mechanisms of disease: angiogenesis in inflammatory diseases. Nat. Clin. Pract. Rheumatol., 2007, 3(11), 635-643.
[http://dx.doi.org/10.1038/ncprheum0647] [PMID: 17968334]

Bielenberg, D.R.; Zetter, B.R. The contribution of angiogenesis to the process of metastasis. Cancer J., 2015, 21(4), 267-273.
[http://dx.doi.org/10.1097/PPO.0000000000000138] [PMID: 26222078]

Bikfalvi, A. Significance of angiogenesis in tumour progression and metastasis. Eur. J. Cancer, 1995, 31A(7-8), 1101-1104.
[http://dx.doi.org/10.1016/0959-8049(95)00169-J] [PMID: 7577000]

Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1995, 1(1), 27-31.
[http://dx.doi.org/10.1038/nm0195-27] [PMID: 7584949]

Baluk, P.; Hashizume, H.; McDonald, D.M. Cellular abnormalities of blood vessels as targets in cancer. Curr. Opin. Genet. Dev., 2005, 15(1), 102-111.
[http://dx.doi.org/10.1016/j.gde.2004.12.005] [PMID: 15661540]

Hillen, F.; Griffioen, A.W. Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev., 2007, 26(3-4), 489-502.
[http://dx.doi.org/10.1007/s10555-007-9094-7] [PMID: 17717633]

Kerbel, R.; Folkman, J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer, 2002, 2(10), 727-739.
[http://dx.doi.org/10.1038/nrc905] [PMID: 12360276]

Folkman, J. Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov., 2007, 6(4), 273-286.
[http://dx.doi.org/10.1038/nrd2115] [PMID: 17396134]

El-Kenawi, A.E.; El-Remessy, A.B. Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales. Br. J. Pharmacol., 2013, 170(4), 712-729.
[http://dx.doi.org/10.1111/bph.12344] [PMID: 23962094]

Roskoski, R., Jr Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem. Biophys. Res. Commun., 2007, 356(2), 323-328.
[http://dx.doi.org/10.1016/j.bbrc.2007.02.156] [PMID: 17367763]

Mousa, S.A.; Davis, P.J. Angiogenesis and Anti-Angiogenesis Strategies in Cancer; Elsevier Inc.: Amsterdam, 2017, pp. 1-19.

Galanina, N.; Petrich, A.; Nabhan, C. The evolving role of lenalidomide in non-Hodgkin lymphoma. Leuk. Lymphoma, 2016, 57(7), 1507-1516.
[http://dx.doi.org/10.3109/10428194.2016.1146949] [PMID: 26902680]

Witzig, T.E.; Nowakowski, G.S.; Habermann, T.M.; Goy, A.; Hernandez-Ilizaliturri, F.J.; Chiappella, A.; Vitolo, U.; Fowler, N.; Czuczman, M.S. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. Ann. Oncol., 2015, 26(8), 1667-1677.
[http://dx.doi.org/10.1093/annonc/mdv102] [PMID: 25712458]

Vogel, A.; Rimassa, L.; Sun, H-C.; Abou-Alfa, G.K.; El-Khoueiry, A.B.; Pinato, D.J. Clinical value of atezolizumab + bevacizumab for first-line unresectable hepatocellular carcinoma (HCC): a network meta-analysis. J. Clin. Oncol., 2020, 38(15), 4585.
[http://dx.doi.org/10.1200/JCO.2020.38.15_suppl.4585]

Johnson, D.H.; Fehrenbacher, L.; Novotny, W.F.; Herbst, R.S.; Nemunaitis, J.J.; Jablons, D.M.; Langer, C.J.; DeVore, R.F., III; Gaudreault, J.; Damico, L.A.; Holmgren, E.; Kabbinavar, F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol., 2004, 22(11), 2184-2191.
[http://dx.doi.org/10.1200/JCO.2004.11.022] [PMID: 15169807]

Cohen, M.H.; Gootenberg, J.; Keegan, P.; Pazdur, R. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist, 2007, 12(6), 713-718.
[http://dx.doi.org/10.1634/theoncologist.12-6-713] [PMID: 17602060]

Zhou, M.; Yu, P.; Qu, X.; Liu, Y.; Zhang, J. Phase III trials of standard chemotherapy with or without bevacizumab for ovarian cancer: a meta-analysis. PLoS One, 2013, 8(12)e81858
[http://dx.doi.org/10.1371/journal.pone.0081858] [PMID: 24324725]

Althoff, E.; Phillips, F. Novartis receives first ever FDA approval; Novartis Int AG Novartis Glob Commun, 2017.

Zheng, P.P.; Kros, J.M.; Li, J. Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts. Drug Discov. Today, 2018, 23(6), 1175-1182.
[http://dx.doi.org/10.1016/j.drudis.2018.02.012] [PMID: 29501911]

Pol, J.; Kroemer, G.; Galluzzi, L. First oncolytic virus approved for melanoma immunotherapy. OncoImmunology, 2015, 5(1)e1115641
[http://dx.doi.org/10.1080/2162402X.2015.1115641] [PMID: 26942095]

U.S. Food and Drug Administration. FDA approves first-of-its-kind product for the treatment of melanoma; US Food Drug Adm, 2017.

Cheever, M.A.; Higano, C.S. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin. Cancer Res., 2011, 17(11), 3520-3526.
[http://dx.doi.org/10.1158/1078-0432.CCR-10-3126] [PMID: 21471425]

Brower, V. Approval of provenge seen as first step for cancer treatment vaccines. J. Natl. Cancer Inst., 2010, 102(15), 1108-1110.
[http://dx.doi.org/10.1093/jnci/djq295] [PMID: 20668267]

Jarosławski, S.; Toumi, M. Sipuleucel-T (Provenge®)-autopsy of an innovative paradigm change in cancer treatment: why a single-product biotech company failed to capitalize on its breakthrough invention. BioDrugs, 2015, 29(5), 301-307.
[http://dx.doi.org/10.1007/s40259-015-0140-7] [PMID: 26403092]

Hazarika, M.; Chuk, M.K.; Theoret, M.R.; Mushti, S.; He, K.; Weis, S.L.; Putman, A.H.; Helms, W.S.; Cao, X.; Li, H.; Zhao, H.; Zhao, L.; Welch, J.; Graham, L.; Libeg, M.; Sridhara, R.; Keegan, P.; Pazdur, R.U.S. FDA approval summary: nivolumab for treatment of unresectable or metastatic melanoma following progression on ipilimumab. Clin. Cancer Res., 2017, 23(14), 3484-3488.
[http://dx.doi.org/10.1158/1078-0432.CCR-16-0712] [PMID: 28087644]

Sondak, V.K.; Smalley, K.S.M.; Kudchadkar, R.; Grippon, S.; Kirkpatrick, P. Ipilimumab. Nat. Rev. Drug Discov., 2011, 10(6), 411-412.

Camacho, L.H. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations. Cancer Med., 2015, 4(5), 661-672.
[http://dx.doi.org/10.1002/cam4.371] [PMID: 25619164]

Ansell, S.M.; Lesokhin, A.M.; Borrello, I.; Halwani, A.; Scott, E.C.; Gutierrez, M.; Schuster, S.J.; Millenson, M.M.; Cattry, D.; Freeman, G.J.; Rodig, S.J.; Chapuy, B.; Ligon, A.H.; Zhu, L.; Grosso, J.F.; Kim, S.Y.; Timmerman, J.M.; Shipp, M.A.; Armand, P. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N. Engl. J. Med., 2015, 372(4), 311-319.
[http://dx.doi.org/10.1056/NEJMoa1411087] [PMID: 25482239]

Simeone, E.; Ascierto, P.A. Anti-PD-1 and PD-L1 antibodies in metastatic melanoma. Melanoma Manag., 2017, 4(4), 175-178.
[http://dx.doi.org/10.2217/mmt-2017-0018] [PMID: 30190923]

Brahmer, J.R.; Tykodi, S.S.; Chow, L.Q.M.; Hwu, W.J.; Topalian, S.L.; Hwu, P.; Drake, C.G.; Camacho, L.H.; Kauh, J.; Odunsi, K.; Pitot, H.C.; Hamid, O.; Bhatia, S.; Martins, R.; Eaton, K.; Chen, S.; Salay, T.M.; Alaparthy, S.; Grosso, J.F.; Korman, A.J.; Parker, S.M.; Agrawal, S.; Goldberg, S.M.; Pardoll, D.M.; Gupta, A.; Wigginton, J.M. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med., 2012, 366(26), 2455-2465.
[http://dx.doi.org/10.1056/NEJMoa1200694] [PMID: 22658128]

Lee, H.T.; Lee, J.Y.; Lim, H.; Lee, S.H.; Moon, Y.J.; Pyo, H.J.; Ryu, S.E.; Shin, W.; Heo, Y.S. Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Sci. Rep., 2017, 7(1), 5532.
[http://dx.doi.org/10.1038/s41598-017-06002-8] [PMID: 28717238]

Syed, Y.Y. Durvalumab: first global approval. Drugs, 2017, 77(12), 1369-1376.
[http://dx.doi.org/10.1007/s40265-017-0782-5] [PMID: 28643244]

Presta, L.G.; Chen, H.; O’Connor, S.J.; Chisholm, V.; Meng, Y.G.; Krummen, L.; Winkler, M.; Ferrara, N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res., 1997, 57(20), 4593-4599.
[PMID: 9377574]

Escudier, B.; Pluzanska, A.; Koralewski, P.; Ravaud, A.; Bracarda, S.; Szczylik, C.; Chevreau, C.; Filipek, M.; Melichar, B.; Bajetta, E.; Gorbunova, V.; Bay, J.O.; Bodrogi, I.; Jagiello-Gruszfeld, A.; Moore, N. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet, 2007, 370(9605), 2103-2111.
[http://dx.doi.org/10.1016/S0140-6736(07)61904-7] [PMID: 18156031]

de Oliveira Dias, J.R.; de Andrade, G.C.; Novais, E.A.; Farah, M.E.; Rodrigues, E.B. Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept. Int. J. Retina Vitreous, 2016, 2(1), 3.
[http://dx.doi.org/10.1186/s40942-016-0026-y] [PMID: 27847621]

Thai, H.T.; Veyrat-Follet, C.; Mentré, F.; Comets, E. Population pharmacokinetic analysis of free and bound aflibercept in patients with advanced solid tumors. Cancer Chemother. Pharmacol., 2013, 72(1), 167-180.
[http://dx.doi.org/10.1007/s00280-013-2182-1] [PMID: 23673444]

Clark, J.W.; Eder, J.P.; Ryan, D.; Lathia, C.; Lenz, H.J. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin. Cancer Res., 2005, 11(15), 5472-5480.
[http://dx.doi.org/10.1158/1078-0432.CCR-04-2658] [PMID: 16061863]

Llovet, J.M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J.F.; de Oliveira, A.C.; Santoro, A.; Raoul, J.L.; Forner, A.; Schwartz, M.; Porta, C.; Zeuzem, S.; Bolondi, L.; Greten, T.F.; Galle, P.R.; Seitz, J.F.; Borbath, I.; Häussinger, D.; Giannaris, T.; Shan, M.; Moscovici, M.; Voliotis, D.; Bruix, J. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med., 2008, 359(4), 378-390.
[http://dx.doi.org/10.1056/NEJMoa0708857] [PMID: 18650514]

Faivre, S.; Delbaldo, C.; Vera, K.; Robert, C.; Lozahic, S.; Lassau, N.; Bello, C.; Deprimo, S.; Brega, N.; Massimini, G.; Armand, J.P.; Scigalla, P.; Raymond, E. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol., 2006, 24(1), 25-35.
[http://dx.doi.org/10.1200/JCO.2005.02.2194] [PMID: 16314617]

Atkins, M.; Jones, C.A.; Kirkpatrick, P. Sunitinib maleate. Nat. Rev. Drug Discov., 2006, 5(4), 279-280.
[http://dx.doi.org/10.1038/nrd2012] [PMID: 16628834]

Keating, G.M. Axitinib: a review in advanced renal cell carcinoma. Drugs, 2015, 75(16), 1903-1913.
[http://dx.doi.org/10.1007/s40265-015-0483-x] [PMID: 26487541]

Gunnarsson, O.; Pfanzelter, N.R.; Cohen, R.B.; Keefe, S.M. Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma. Cancer Manag. Res., 2015, 7, 65-73.
[http://dx.doi.org/10.2147/CMAR.S74202] [PMID: 25709499]

Casak, S.J.; Fashoyin-Aje, I.; Lemery, S.J.; Zhang, L.; Jin, R.; Li, H.; Zhao, L.; Zhao, H.; Zhang, H.; Chen, H.; He, K.; Dougherty, M.; Novak, R.; Kennett, S.; Khasar, S.; Helms, W.; Keegan, P.; Pazdur, R. FDA approval summary: ramucirumab for gastric cancer. Clin. Cancer Res., 2015, 21(15), 3372-3376.
[http://dx.doi.org/10.1158/1078-0432.CCR-15-0600] [PMID: 26048277]

Diaz-Serrano, A.; Riesco-Martinez, M.C.; Garcia-Carbonero, R. The safety and efficacy of ramucirumab for the treatment of metastatic colorectal cancer. Expert Rev. Anticancer Ther., 2016, 16(6), 585-595.
[http://dx.doi.org/10.1080/14737140.2016.1182430] [PMID: 27144874]

Ranieri, G.; Mammì, M.; Donato Di Paola, E.; Russo, E.; Gallelli, L.; Citraro, R.; Gadaleta, C.D.; Marech, I.; Ammendola, M.; De Sarro, G. Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: a new treatment for metastatic soft tissue sarcoma. Crit. Rev. Oncol. Hematol., 2014, 89(2), 322-329.
[http://dx.doi.org/10.1016/j.critrevonc.2013.08.012] [PMID: 24041629]

Sonpavde, G.; Hutson, T.E.; Sternberg, C.N. Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Expert Opin. Investig. Drugs, 2008, 17(2), 253-261.
[http://dx.doi.org/10.1517/13543784.17.2.253] [PMID: 18230058]

Yakes, F.M.; Chen, J.; Tan, J.; Yamaguchi, K.; Shi, Y.; Yu, P.; Qian, F.; Chu, F.; Bentzien, F.; Cancilla, B.; Orf, J.; You, A.; Laird, A.D.; Engst, S.; Lee, L.; Lesch, J.; Chou, Y.C.; Joly, A.H. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol. Cancer Ther., 2011, 10(12), 2298-2308.
[http://dx.doi.org/10.1158/1535-7163.MCT-11-0264] [PMID: 21926191]

Grüllich, C. Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor. Recent Results Cancer Res., 2014, 201, 207-214.
[http://dx.doi.org/10.1007/978-3-642-54490-3_12] [PMID: 24756794]

Choueiri, T.K.; Escudier, B.; Powles, T.; Mainwaring, P.N.; Rini, B.I.; Donskov, F.; Hammers, H.; Hutson, T.E.; Lee, J.L.; Peltola, K.; Roth, B.J.; Bjarnason, G.A.; Géczi, L.; Keam, B.; Maroto, P.; Heng, D.Y.; Schmidinger, M.; Kantoff, P.W.; Borgman-Hagey, A.; Hessel, C.; Scheffold, C.; Schwab, G.M.; Tannir, N.M.; Motzer, R.J. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med., 2015, 373(19), 1814-1823.
[http://dx.doi.org/10.1056/NEJMoa1510016] [PMID: 26406150]

Beaver, J.A.; Park, B.H. The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer. Future Oncol., 2012, 8(6), 651-657.

Baselga, J.; Campone, M.; Piccart, M.; Burris, H.A., III; Rugo, H.S.; Sahmoud, T.; Noguchi, S.; Gnant, M.; Pritchard, K.I.; Lebrun, F.; Beck, J.T.; Ito, Y.; Yardley, D.; Deleu, I.; Perez, A.; Bachelot, T.; Vittori, L.; Xu, Z.; Mukhopadhyay, P.; Lebwohl, D.; Hortobagyi, G.N. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med., 2012, 366(6), 520-529.
[http://dx.doi.org/10.1056/NEJMoa1109653] [PMID: 22149876]

Zhu, Y.X.; Kortuem, K.M.; Stewart, A.K. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk. Lymphoma, 2013, 54(4), 683-687.
[http://dx.doi.org/10.3109/10428194.2012.728597] [PMID: 22966948]

Lu, L.; Payvandi, F.; Wu, L.; Zhang, L.H.; Hariri, R.J.; Man, H.W.; Chen, R.S.; Muller, G.W.; Hughes, C.C.; Stirling, D.I.; Schafer, P.H.; Bartlett, J.B. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc. Res., 2009, 77(2), 78-86.
[http://dx.doi.org/10.1016/j.mvr.2008.08.003] [PMID: 18805433]

Cabanillas, M.E.; Habra, M.A. Lenvatinib: role in thyroid cancer and other solid tumors. Cancer Treat. Rev., 2016, 42, 47-55.
[http://dx.doi.org/10.1016/j.ctrv.2015.11.003] [PMID: 26678514]

Scott, L.J. Lenvatinib: first global approval. Drugs, 2015, 75(5), 553-560.
[http://dx.doi.org/10.1007/s40265-015-0383-0] [PMID: 25795101]

Hotta, K.; Ueyama, J.; Tatsumi, Y.; Tsukiyama, I.; Sugiura, Y.; Saito, H.; Matsuura, K.; Hasegawa, T. Lack of contribution of multidrug resistance-associated protein and organic anion-transporting polypeptide to pharmacokinetics of regorafenib, a novel multi-kinase inhibitor, in rats. Anticancer Res., 2015, 35(9), 4681-4689.
[PMID: 26254357]

Strumberg, D.; Scheulen, M.E.; Schultheis, B.; Richly, H.; Frost, A.; Büchert, M.; Christensen, O.; Jeffers, M.; Heinig, R.; Boix, O.; Mross, K. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br. J. Cancer, 2012, 106(11), 1722-1727.
[http://dx.doi.org/10.1038/bjc.2012.153] [PMID: 22568966]

Demetri, G.D.; Reichardt, P.; Kang, Y.K.; Blay, J.Y.; Rutkowski, P.; Gelderblom, H.; Hohenberger, P.; Leahy, M.; von Mehren, M.; Joensuu, H.; Badalamenti, G.; Blackstein, M.; Le Cesne, A.; Schöffski, P.; Maki, R.G.; Bauer, S.; Nguyen, B.B.; Xu, J.; Nishida, T.; Chung, J.; Kappeler, C.; Kuss, I.; Laurent, D.; Casali, P.G. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, 2013, 381(9863), 295-302.
[http://dx.doi.org/10.1016/S0140-6736(12)61857-1] [PMID: 23177515]

Palumbo, A.; Facon, T.; Sonneveld, P.; Bladè, J.; Offidani, M.; Gay, F.; Moreau, P.; Waage, A.; Spencer, A.; Ludwig, H.; Boccadoro, M.; Harousseau, J.L. Thalidomide for treatment of multiple myeloma: 10 years later. Blood, 2008, 111(8), 3968-3977.
[http://dx.doi.org/10.1182/blood-2007-10-117457] [PMID: 18245666]

Hjorth, M.; Hjertner, Ø.; Knudsen, L.M.; Gulbrandsen, N.; Holmberg, E.; Pedersen, P.T.; Andersen, N.F.; Andréasson, B.; Billström, R.; Carlson, K.; Carlsson, M.S.; Flogegård, M.; Forsberg, K.; Gimsing, P.; Karlsson, T.; Linder, O.; Nahi, H.; Othzén, A.; Swedin, A. Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. Eur. J. Haematol., 2012, 88(6), 485-496.
[http://dx.doi.org/10.1111/j.1600-0609.2012.01775.x] [PMID: 22404182]

Robinson, B.G.; Paz-Ares, L.; Krebs, A.; Vasselli, J.; Haddad, R. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J. Clin. Endocrinol. Metab., 2010, 95(6), 2664-2671.
[http://dx.doi.org/10.1210/jc.2009-2461] [PMID: 20371662]

Sathornsumetee, S.; Rich, J.N. Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy. Drugs Today (Barc), 2006, 42(10), 657-670.
[http://dx.doi.org/10.1358/dot.2006.42.10.1025318] [PMID: 17136225]

Ragon, B.K.; DiNardo, C.D. Targeting IDH1 and IDH2 mutations in acute myeloid leukemia. Curr. Hematol. Malig. Rep., 2017, 12(6), 537-546.
[http://dx.doi.org/10.1007/s11899-017-0418-6]

Toplin, J.; Drafahl, K.; Eibl, J.; Fjeld, C.; Yager, T.; McAdams, S. Development and validation of highly sensitive Mrdx BCR-ABL test for monitoring deep molecular response in patients with chronic myeloid leukemia. Blood, 2013, 122(21), 2617-2617.
[http://dx.doi.org/10.1182/blood.V122.21.2617.2617]

Philippidis, A. 8 companion diagnostic developers making a mark; Clin. Omi, 2019, pp. 34-38.

Vargas, A.C.; Maclean, F.M.; Sioson, L.; Tran, D.; Bonar, F.; Mahar, A.; Cheah, A.L.; Russell, P.; Grimison, P.; Richardson, L.; Gill, A.J. Prevalence of PD-L1 expression in matched recurrent and/or metastatic sarcoma samples and in a range of selected sarcomas subtypes. PLoS One, 2020, 15(4)e0222551
[http://dx.doi.org/10.1371/journal.pone.0222551] [PMID: 32294103]

Allegretti, M.; Fabi, A.; Buglioni, S.; Martayan, A.; Conti, L.; Pescarmona, E.; Ciliberto, G.; Giacomini, P. Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations. J. Exp. Clin. Cancer Res., 2018, 37(1), 47.
[http://dx.doi.org/10.1186/s13046-018-0702-x] [PMID: 29506529]

Wu, H-X.; Wang, Z-X.; Zhao, Q.; Chen, D-L.; He, M-M.; Yang, L-P.; Wang, Y.N.; Jin, Y.; Ren, C.; Luo, H.Y.; Wang, Z.Q.; Wang, F. Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers. Ann. Transl. Med., 2019, 7(22), 640.
[http://dx.doi.org/10.21037/atm.2019.10.116] [PMID: 31930041]

Carcinoma, B.; Lung, N.C. Ventana Pd-L1 (Sp142). Assay, 2020, 1, 1-15.

Vennapusa, B.; Baker, B.; Kowanetz, M.; Boone, J.; Menzl, I.; Bruey, J.M.; Fine, G.; Mariathasan, S.; McCaffery, I.; Mocci, S.; Rost, S.; Smith, D.; Dennis, E.; Tang, S.Y.; Damadzadeh, B.; Walker, E.; Hegde, P.S.; Williams, J.A.; Koeppen, H.; Boyd, Z. Development of a PD-L1 complementary diagnostic immunohistochemistry assay (SP142) for atezolizumab. Appl. Immunohistochem. Mol. Morphol., 2019, 27(2), 92-100.
[http://dx.doi.org/10.1097/PAI.0000000000000594] [PMID: 29346180]

Hirsch, F.R.; McElhinny, A.; Stanforth, D.; Ranger-Moore, J.; Jansson, M.; Kulangara, K.; Richardson, W.; Towne, P.; Hanks, D.; Vennapusa, B.; Mistry, A.; Kalamegham, R.; Averbuch, S.; Novotny, J.; Rubin, E.; Emancipator, K.; McCaffery, I.; Williams, J.A.; Walker, J.; Longshore, J.; Tsao, M.S.; Kerr, K.M. PD-L1 immunohistochemistry assays for lung cancer: results from Phase 1 of the blueprint PD-L1 IHC assay comparison project. J. Thorac. Oncol., 2017, 12(2), 208-222.
[http://dx.doi.org/10.1016/j.jtho.2016.11.2228] [PMID: 27913228]

Ahn, E.R.; Wang, E.; Glück, S. .Is the improved efficacy of trastuzumab and lapatinib combination worth the added toxicity? a discussion of current evidence, recommendations, and ethical issues regarding dual HER2-targeted therapy. Breast Cancer Basic Clin Res, 2012, BCBCR-S9301.,

Agur, Z.; Elishmereni, M.; Kheifetz, Y. Personalizing oncology treatments by predicting drug efficacy, side-effects, and improved therapy: mathematics, statistics, and their integration. Wiley Interdiscip. Rev. Syst. Biol. Med., 2014, 6(3), 239-253.
[http://dx.doi.org/10.1002/wsbm.1263] [PMID: 24604755]

Baldock, A.L.; Rockne, R.C.; Boone, A.D.; Neal, M.L.; Hawkins-Daarud, A.; Corwin, D.M.; Bridge, C.A.; Guyman, L.A.; Trister, A.D.; Mrugala, M.M.; Rockhill, J.K.; Swanson, K.R. From patient-specific mathematical neuro-oncology to precision medicine. Front. Oncol., 2013, 3, 62.
[http://dx.doi.org/10.3389/fonc.2013.00062] [PMID: 23565501]

Kronik, N.; Kogan, Y.; Elishmereni, M.; Halevi-Tobias, K.; Vuk-Pavlović, S.; Agur, Z. Predicting outcomes of prostate cancer immunotherapy by personalized mathematical models. PLoS One, 2010, 5(12)e15482
[http://dx.doi.org/10.1371/journal.pone.0015482] [PMID: 21151630]

Beumer, J.H. Without therapeutic drug monitoring, there is no personalized cancer care. Clin. Pharmacol. Ther., 2013, 93(3), 228-230.
[http://dx.doi.org/10.1038/clpt.2012.243] [PMID: 23419487]

Barbolosi, D.; Ciccolini, J.; Lacarelle, B.; Barlési, F.; André, N. Computational oncology-mathematical modelling of drug regimens for precision medicine. Nat. Rev. Clin. Oncol., 2016, 13(4), 242-254.
[http://dx.doi.org/10.1038/nrclinonc.2015.204] [PMID: 26598946]

Canal, P.; Chatelut, E.; Guichard, S. Practical treatment guide for dose individualisation in cancer chemotherapy. Drugs, 1998, 56(6), 1019-1038.
[http://dx.doi.org/10.2165/00003495-199856060-00006] [PMID: 9878990]

Li, J.; Zhao, M.; He, P.; Hidalgo, M.; Baker, S.D. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin. Cancer Res., 2007, 13(12), 3731-3737.
[http://dx.doi.org/10.1158/1078-0432.CCR-07-0088] [PMID: 17575239]

Mollard, S.; Benzekry, S.; Giacometti, S.; Faivre, C.; Hubert, F.; Ciccolini, J. Abstract 3677: Model-based optimization of combined antiangiogenic + cytotoxics modalities: application to the bevacizumab-paclitaxel association in breast cancer models. Cancer Res., 2014, 74(19), 3677-3677.

Chen, R.; Snyder, M. Promise of personalized omics to precision medicine. Wiley Interdiscip. Rev. Syst. Biol. Med., 2013, 5(1), 73-82.
[http://dx.doi.org/10.1002/wsbm.1198] [PMID: 23184638]

Nicora, G.; Vitali, F.; Dagliati, A.; Geifman, N.; Bellazzi, R. Integrated multi-omics analyses in oncology: a review of machine learning methods and tools. Front. Oncol., 2020, 10, 1030.
[http://dx.doi.org/10.3389/fonc.2020.01030] [PMID: 32695678]

Granja, J.M.; Klemm, S.; McGinnis, L.M.; Kathiria, A.S.; Mezger, A.; Corces, M.R.; Parks, B.; Gars, E.; Liedtke, M.; Zheng, G.X.Y.; Chang, H.Y.; Majeti, R.; Greenleaf, W.J. Single-cell multiomic analysis identifies regulatory programs in mixed-phenotype acute leukemia. Nat. Biotechnol., 2019, 37(12), 1458-1465.
[http://dx.doi.org/10.1038/s41587-019-0332-7] [PMID: 31792411]

Chen, B.; Wei, W.; Ma, L.; Yang, B.; Gill, R.M.; Chua, M.S.; Butte, A.J.; So, S. Computational discovery of niclosamide ethanolamine, a repurposed drug candidate that reduces growth of hepatocellular carcinoma cells in vitro and in mice by inhibiting cell division cycle 37 signaling. Gastroenterology, 2017, 152(8), 2022-2036.
[http://dx.doi.org/10.1053/j.gastro.2017.02.039] [PMID: 28284560]

Olivier, M.; Asmis, R.; Hawkins, G.A.; Howard, T.D.; Cox, L.A. The need for multi-omics biomarker signatures in precision medicine. Int. J. Mol. Sci., 2019, 20(19), 4781.
[http://dx.doi.org/10.3390/ijms20194781] [PMID: 31561483]

Zhang, K.; Wang, H. Cancer Genome Atlas Pan-cancer analysis project.Chinese J. Lung Cancer, 2015, 18(4).,

Shah, S.P.; Roth, A.; Goya, R.; Oloumi, A.; Ha, G.; Zhao, Y.; Turashvili, G.; Ding, J.; Tse, K.; Haffari, G.; Bashashati, A.; Prentice, L.M.; Khattra, J.; Burleigh, A.; Yap, D.; Bernard, V.; McPherson, A.; Shumansky, K.; Crisan, A.; Giuliany, R.; Heravi-Moussavi, A.; Rosner, J.; Lai, D.; Birol, I.; Varhol, R.; Tam, A.; Dhalla, N.; Zeng, T.; Ma, K.; Chan, S.K.; Griffith, M.; Moradian, A.; Cheng, S.W.; Morin, G.B.; Watson, P.; Gelmon, K.; Chia, S.; Chin, S.F.; Curtis, C.; Rueda, O.M.; Pharoah, P.D.; Damaraju, S.; Mackey, J.; Hoon, K.; Harkins, T.; Tadigotla, V.; Sigaroudinia, M.; Gascard, P.; Tlsty, T.; Costello, J.F.; Meyer, I.M.; Eaves, C.J.; Wasserman, W.W.; Jones, S.; Huntsman, D.; Hirst, M.; Caldas, C.; Marra, M.A.; Aparicio, S. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature, 2012, 486(7403), 395-399.
[http://dx.doi.org/10.1038/nature10933] [PMID: 22495314]

Jain, K.K. Role of pharmacoproteomics in the development of personalized medicine. Pharmacogenomics, 2004, 5(3), 331-336.
[http://dx.doi.org/10.1517/phgs.5.3.331.29830] [PMID: 15102547]

Ali, M.; Khan, S.A.; Wennerberg, K.; Aittokallio, T. Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach. Bioinformatics, 2018, 34(8), 1353-1362.
[http://dx.doi.org/10.1093/bioinformatics/btx766] [PMID: 29186355]

Hegi, M.E.; Diserens, A.C.; Gorlia, T.; Hamou, M.F.; de Tribolet, N.; Weller, M.; Kros, J.M.; Hainfellner, J.A.; Mason, W.; Mariani, L.; Bromberg, J.E.; Hau, P.; Mirimanoff, R.O.; Cairncross, J.G.; Janzer, R.C.; Stupp, R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med., 2005, 352(10), 997-1003.
[http://dx.doi.org/10.1056/NEJMoa043331] [PMID: 15758010]

Padovani de Souza, K.; Setubal, J.C. Ponce de Leon F de Carvalho, A.C.; Oliveira, G.; Chateau, A.; Alves, R. Machine learning meets genome assembly. Brief. Bioinform., 2019, 20(6), 2116-2129.
[http://dx.doi.org/10.1093/bib/bby072] [PMID: 30137230]

Bello, G.A.; Dawes, T.J.W.; Duan, J.; Biffi, C.; de Marvao, A.; Howard, L.S.G.E.; Gibbs, J.S.R.; Wilkins, M.R.; Cook, S.A.; Rueckert, D.; O’Regan, D.P. Deep learning cardiac motion analysis for human survival prediction. Nat. Mach. Intell., 2019, 1(2), 95-104.
[http://dx.doi.org/10.1038/s42256-019-0019-2] [PMID: 30801055]

Chang, P.; Grinband, J.; Weinberg, B.D.; Bardis, M.; Khy, M.; Cadena, G.; Su, M.Y.; Cha, S.; Filippi, C.G.; Bota, D.; Baldi, P.; Poisson, L.M.; Jain, R.; Chow, D. Deep-learning convolutional neural networks accurately classify genetic mutations in gliomas. AJNR Am. J. Neuroradiol., 2018, 39(7), 1201-1207.
[http://dx.doi.org/10.3174/ajnr.A5667] [PMID: 29748206]

Esteva, A.; Kuprel, B.; Novoa, R.A.; Ko, J.; Swetter, S.M.; Blau, H.M.; Thrun, S. Dermatologist-level classification of skin cancer with deep neural networks. Nature, 2017, 542(7639), 115-118.
[http://dx.doi.org/10.1038/nature21056] [PMID: 28117445]

Strodthoff, N.; Strodthoff, C. Detecting and interpreting myocardial infarction using fully convolutional neural networks. Physiol. Meas., 2019, 40(1)015001
[http://dx.doi.org/10.1088/1361-6579/aaf34d] [PMID: 30523982]

Boža, V.; Brejová, B.; Vinař, T. DeepNano: deep recurrent neural networks for base calling in MinION nanopore reads. PLoS One, 2017, 12(6)e0178751
[http://dx.doi.org/10.1371/journal.pone.0178751] [PMID: 28582401]

Kosmicki, J.A.; Sochat, V.; Duda, M.; Wall, D.P. Searching for a minimal set of behaviors for autism detection through feature selection-based machine learning. Transl. Psychiatry, 2015, 5(2)e514
[http://dx.doi.org/10.1038/tp.2015.7] [PMID: 25710120]

Wall, D.P.; Dally, R.; Luyster, R.; Jung, J.Y.; Deluca, T.F. Use of artificial intelligence to shorten the behavioral diagnosis of autism. PLoS One, 2012, 7(8)e43855
[http://dx.doi.org/10.1371/journal.pone.0043855] [PMID: 22952789]

Bone, D.; Goodwin, M.S.; Black, M.P.; Lee, C.C.; Audhkhasi, K.; Narayanan, S. Applying machine learning to facilitate autism diagnostics: pitfalls and promises. J. Autism Dev. Disord., 2015, 45(5), 1121-1136.
[http://dx.doi.org/10.1007/s10803-014-2268-6] [PMID: 25294649]

Mazurek, M.O.; Curran, A.; Burnette, C.; Sohl, K. ECHO autism STAT: accelerating early access to autism diagnosis. J. Autism Dev. Disord., 2019, 49(1), 127-137.
[http://dx.doi.org/10.1007/s10803-018-3696-5] [PMID: 30043354]

Rizzi, R.; Cairo, M.; Makinen, V.; Tomescu, A.I.; Valenzuela, D. Hardness of covering alignment: phase transition in post-sequence genomics. IEEE/ACM Trans. Comput. Biol. Bioinform., 2019, 16(1), 23-30.

Gurovich, Y.; Hanani, Y.; Bar, O.; Nadav, G.; Fleischer, N.; Gelbman, D.; Basel-Salmon, L.; Krawitz, P.M.; Kamphausen, S.B.; Zenker, M.; Bird, L.M.; Gripp, K.W. Identifying facial phenotypes of genetic disorders using deep learning. Nat. Med., 2019, 25(1), 60-64.
[http://dx.doi.org/10.1038/s41591-018-0279-0] [PMID: 30617323]

Gagnon, M.P.; Ghandour, K.; Talla, P.K.; Simonyan, D.; Godin, G.; Labrecque, M.; Ouimet, M.; Rousseau, M. Electronic health record acceptance by physicians: testing an integrated theoretical model. J. Biomed. Inform., 2014, 48, 17-27.
[http://dx.doi.org/10.1016/j.jbi.2013.10.010] [PMID: 24184678]

Verma, M. Epigenome-Wide Association Studies (EWAS) in cancer. Curr. Genomics, 2012, 13(4), 308-313.
[http://dx.doi.org/10.2174/138920212800793294] [PMID: 23204920]

Lander, E.S.; Linton, L.M.; Birren, B.; Nusbaum, C.; Zody, M.C.; Baldwin, J.; Devon, K.; Dewar, K.; Doyle, M.; FitzHugh, W.; Funke, R.; Gage, D.; Harris, K.; Heaford, A.; Howland, J.; Kann, L.; Lehoczky, J.; LeVine, R.; McEwan, P.; McKernan, K.; Meldrim, J.; Mesirov, J.P.; Miranda, C.; Morris, W.; Naylor, J.; Raymond, C.; Rosetti, M.; Santos, R.; Sheridan, A.; Sougnez, C.; Stange-Thomann, Y.; Stojanovic, N.; Subramanian, A.; Wyman, D.; Rogers, J.; Sulston, J.; Ainscough, R.; Beck, S.; Bentley, D.; Burton, J.; Clee, C.; Carter, N.; Coulson, A.; Deadman, R.; Deloukas, P.; Dunham, A.; Dunham, I.; Durbin, R.; French, L.; Grafham, D.; Gregory, S.; Hubbard, T.; Humphray, S.; Hunt, A.; Jones, M.; Lloyd, C.; McMurray, A.; Matthews, L.; Mercer, S.; Milne, S.; Mullikin, J.C.; Mungall, A.; Plumb, R.; Ross, M.; Shownkeen, R.; Sims, S.; Waterston, R.H.; Wilson, R.K.; Hillier, L.W.; McPherson, J.D.; Marra, M.A.; Mardis, E.R.; Fulton, L.A.; Chinwalla, A.T.; Pepin, K.H.; Gish, W.R.; Chissoe, S.L.; Wendl, M.C.; Delehaunty, K.D.; Miner, T.L.; Delehaunty, A.; Kramer, J.B.; Cook, L.L.; Fulton, R.S.; Johnson, D.L.; Minx, P.J.; Clifton, S.W.; Hawkins, T.; Branscomb, E.; Predki, P.; Richardson, P.; Wenning, S.; Slezak, T.; Doggett, N.; Cheng, J.F.; Olsen, A.; Lucas, S.; Elkin, C.; Uberbacher, E.; Frazier, M.; Gibbs, R.A.; Muzny, D.M.; Scherer, S.E.; Bouck, J.B.; Sodergren, E.J.; Worley, K.C.; Rives, C.M.; Gorrell, J.H.; Metzker, M.L.; Naylor, S.L.; Kucherlapati, R.S.; Nelson, D.L.; Weinstock, G.M.; Sakaki, Y.; Fujiyama, A.; Hattori, M.; Yada, T.; Toyoda, A.; Itoh, T.; Kawagoe, C.; Watanabe, H.; Totoki, Y.; Taylor, T.; Weissenbach, J.; Heilig, R.; Saurin, W.; Artiguenave, F.; Brottier, P.; Bruls, T.; Pelletier, E.; Robert, C.; Wincker, P.; Smith, D.R.; Doucette-Stamm, L.; Rubenfield, M.; Weinstock, K.; Lee, H.M.; Dubois, J.; Rosenthal, A.; Platzer, M.; Nyakatura, G.; Taudien, S.; Rump, A.; Yang, H.; Yu, J.; Wang, J.; Huang, G.; Gu, J.; Hood, L.; Rowen, L.; Madan, A.; Qin, S.; Davis, R.W.; Federspiel, N.A.; Abola, A.P.; Proctor, M.J.; Myers, R.M.; Schmutz, J.; Dickson, M.; Grimwood, J.; Cox, D.R.; Olson, M.V.; Kaul, R.; Raymond, C.; Shimizu, N.; Kawasaki, K.; Minoshima, S.; Evans, G.A.; Athanasiou, M.; Schultz, R.; Roe, B.A.; Chen, F.; Pan, H.; Ramser, J.; Lehrach, H.; Reinhardt, R.; McCombie, W.R.; de la Bastide, M.; Dedhia, N.; Blöcker, H.; Hornischer, K.; Nordsiek, G.; Agarwala, R.; Aravind, L.; Bailey, J.A.; Bateman, A.; Batzoglou, S.; Birney, E.; Bork, P.; Brown, D.G.; Burge, C.B.; Cerutti, L.; Chen, H.C.; Church, D.; Clamp, M.; Copley, R.R.; Doerks, T.; Eddy, S.R.; Eichler, E.E.; Furey, T.S.; Galagan, J.; Gilbert, J.G.; Harmon, C.; Hayashizaki, Y.; Haussler, D.; Hermjakob, H.; Hokamp, K.; Jang, W.; Johnson, L.S.; Jones, T.A.; Kasif, S.; Kaspryzk, A.; Kennedy, S.; Kent, W.J.; Kitts, P.; Koonin, E.V.; Korf, I.; Kulp, D.; Lancet, D.; Lowe, T.M.; McLysaght, A.; Mikkelsen, T.; Moran, J.V.; Mulder, N.; Pollara, V.J.; Ponting, C.P.; Schuler, G.; Schultz, J.; Slater, G.; Smit, A.F.; Stupka, E.; Szustakowki, J.; Thierry-Mieg, D.; Thierry-Mieg, J.; Wagner, L.; Wallis, J.; Wheeler, R.; Williams, A.; Wolf, Y.I.; Wolfe, K.H.; Yang, S.P.; Yeh, R.F.; Collins, F.; Guyer, M.S.; Peterson, J.; Felsenfeld, A.; Wetterstrand, K.A.; Patrinos, A.; Morgan, M.J.; de Jong, P.; Catanese, J.J.; Osoegawa, K.; Shizuya, H.; Choi, S.; Chen, Y.J.; Szustakowki, J. Initial sequencing and analysis of the human genome. Nature, 2001, 409(6822), 860-921.
[http://dx.doi.org/10.1038/35057062] [PMID: 11237011]

Coe, B.P.; Stessman, H.A.F.; Sulovari, A.; Geisheker, M.R.; Bakken, T.E.; Lake, A.M.; Dougherty, J.D.; Lein, E.S.; Hormozdiari, F.; Bernier, R.A.; Eichler, E.E. Neurodevelopmental disease genes implicated by de novo mutation and copy number variation morbidity. Nat. Genet., 2019, 51(1), 106-116.
[http://dx.doi.org/10.1038/s41588-018-0288-4] [PMID: 30559488]

Wright, C.F.; McRae, J.F.; Clayton, S.; Gallone, G.; Aitken, S.; FitzGerald, T.W.; Jones, P.; Prigmore, E.; Rajan, D.; Lord, J.; Sifrim, A.; Kelsell, R.; Parker, M.J.; Barrett, J.C.; Hurles, M.E.; FitzPatrick, D.R.; Firth, H.V. Making new genetic diagnoses with old data: iterative reanalysis and reporting from genome-wide data in 1,133 families with developmental disorders. Genet. Med., 2018, 20(10), 1216-1223.
[http://dx.doi.org/10.1038/gim.2017.246] [PMID: 29323667]

Xiong, H.Y.; Alipanahi, B.; Lee, L.J.; Bretschneider, H.; Merico, D.; Yuen, R.K.C.; Hua, Y.; Gueroussov, S.; Najafabadi, H.S.; Hughes, T.R.; Morris, Q.; Barash, Y.; Krainer, A.R.; Jojic, N.; Scherer, S.W.; Blencowe, B.J.; Frey, B.J. RNA splicing. The human splicing code reveals new insights into the genetic determinants of disease. Science, 2015, 347(6218)1254806
[http://dx.doi.org/10.1126/science.1254806] [PMID: 25525159]

Zhou, J.; Troyanskaya, O.G. Predicting effects of noncoding variants with deep learning-based sequence model. Nat. Methods, 2015, 12(10), 931-934.
[http://dx.doi.org/10.1038/nmeth.3547] [PMID: 26301843]

Kircher, M.F.; Hricak, H.; Larson, S.M. Molecular imaging for personalized cancer care. Mol. Oncol., 2012, 6(2), 182-195.
[http://dx.doi.org/10.1016/j.molonc.2012.02.005] [PMID: 22469618]

Kurdziel, K.; Ravizzini, G.; Croft, B.; Tatum, J.; Choyke, P.; Kobayashi, H. The evolving role of nuclear molecular imaging in cancer. Expert Opin. Med. Diagn., 2008, 2(7), 829-842.
[http://dx.doi.org/10.1517/17530059.2.7.829] [PMID: 19122861]

Weiss, S.T.; Shin, M.S. Infrastructure for personalized medicine at partners healthcare. J. Pers. Med., 2016, 6(1), 13.
[http://dx.doi.org/10.3390/jpm6010013] [PMID: 26927187]

Ahn, B.C. Personalized medicine based on theranostic radioiodine molecular imaging for differentiated thyroid cancer. BioMed Res. Int., 2016, 20161680464
[http://dx.doi.org/10.1155/2016/1680464] [PMID: 27239470]

Gould, J.; Getz, G.; Monti, S.; Reich, M.; Mesirov, J.P. Comparative gene marker selection suite. Bioinformatics, 2006, 22(15), 1924-1925.
[http://dx.doi.org/10.1093/bioinformatics/btl196] [PMID: 16709585]

Cavallo, F.; De Giovanni, C.; Nanni, P.; Forni, G.; Lollini, P.L. 2011: the immune hallmarks of cancer. Cancer Immunol. Immunother., 2011, 60(3), 319-326.
[http://dx.doi.org/10.1007/s00262-010-0968-0] [PMID: 21267721]

Henzler, T.; Fink, C. Functional computed tomography in oncology and cardiovascular imaging: a key player in the era of precision medicine and radiogenomics. Eur. J. Radiol., 2015, 84(12), 2345-2346.
[http://dx.doi.org/10.1016/j.ejrad.2015.11.013] [PMID: 26590851]

Rutman, A.M.; Kuo, M.D. Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging. Eur. J. Radiol., 2009, 70(2), 232-241.
[http://dx.doi.org/10.1016/j.ejrad.2009.01.050] [PMID: 19303233]

Penet, M.F.; Krishnamachary, B.; Chen, Z.; Jin, J.; Bhujwalla, Z.M. Molecular imaging of the tumor microenvironment for precision medicine and theranostics. Adv. Cancer Res., 2014, 124, 235-256.
[http://dx.doi.org/10.1016/B978-0-12-411638-2.00007-0] [PMID: 25287691]

Chen, Z.Y.; Wang, Y.X.; Lin, Y.; Zhang, J.S.; Yang, F.; Zhou, Q.L.; Liao, Y.Y. Advance of molecular imaging technology and targeted imaging agent in imaging and therapy. BioMed Res. Int., 2014, 2014819324
[http://dx.doi.org/10.1155/2014/819324] [PMID: 24689058]

James, M.L.; Gambhir, S.S. A molecular imaging primer: modalities, imaging agents, and applications. Physiol. Rev., 2012, 92(2), 897-965.
[http://dx.doi.org/10.1152/physrev.00049.2010] [PMID: 22535898]

Rager, O.; Nkoulou, R.; Exquis, N.; Garibotto, V.; Tabouret-Viaud, C.; Zaidi, H.; Amzalag, G.; Lee-Felker, S.A.; Zilli, T.; Ratib, O. Whole-body SPECT/CT versus planar bone scan with targeted SPECT/CT for metastatic workup. BioMed Res. Int., 2017, 20177039406
[http://dx.doi.org/10.1155/2017/7039406] [PMID: 28812019]

Miyake, K.; Ogawa, D.; Okada, M.; Hatakeyama, T.; Tamiya, T. Usefulness of positron emission tomographic studies for gliomas. Neurol. Med. Chir. (Tokyo), 2016, 56(7), 396-408.
[http://dx.doi.org/10.2176/nmc.ra.2015-0305]

Sung, Y.S.; Park, B.; Choi, Y.; Lim, H.S.; Woo, D.C.; Kim, K.W.; Kim, J.K. Dynamic contrast-enhanced MRI for oncology drug development. J. Magn. Reson. Imaging, 2016, 44(2), 251-264.
[http://dx.doi.org/10.1002/jmri.25173] [PMID: 26854494]

New, S.E.P.; Aikawa, E. Molecular imaging insights into early inflammatory stages of arterial and aortic valve calcification. Circ. Res., 2011, 108(11), 1381-1391.
[http://dx.doi.org/10.1161/CIRCRESAHA.110.234146] [PMID: 21617135]

Hussain, T.; Nguyen, Q.T. Molecular imaging for cancer diagnosis and surgery. Adv. Drug Deliv. Rev., 2014, 66, 90-100.
[http://dx.doi.org/10.1016/j.addr.2013.09.007] [PMID: 24064465]

Hricak, H. Oncologic imaging: a guiding hand of personalized cancer care. Radiology, 2011, 259(3), 633-640.
[http://dx.doi.org/10.1148/radiol.11110252] [PMID: 21493796]

Block, K.I.; Gyllenhaal, C.; Lowe, L.; Amedei, A.; Amin, A.R.M.R.; Amin, A.; Aquilano, K.; Arbiser, J.; Arreola, A.; Arzumanyan, A.; Ashraf, S.S.; Azmi, A.S.; Benencia, F.; Bhakta, D.; Bilsland, A.; Bishayee, A.; Blain, S.W.; Block, P.B.; Boosani, C.S.; Carey, T.E.; Carnero, A.; Carotenuto, M.; Casey, S.C.; Chakrabarti, M.; Chaturvedi, R.; Chen, G.Z.; Chen, H.; Chen, S.; Chen, Y.C.; Choi, B.K.; Ciriolo, M.R.; Coley, H.M.; Collins, A.R.; Connell, M.; Crawford, S.; Curran, C.S.; Dabrosin, C.; Damia, G.; Dasgupta, S.; DeBerardinis, R.J.; Decker, W.K.; Dhawan, P.; Diehl, A.M.E.; Dong, J.T.; Dou, Q.P.; Drew, J.E.; Elkord, E.; El-Rayes, B.; Feitelson, M.A.; Felsher, D.W.; Ferguson, L.R.; Fimognari, C.; Firestone, G.L.; Frezza, C.; Fujii, H.; Fuster, M.M.; Generali, D.; Georgakilas, A.G.; Gieseler, F.; Gilbertson, M.; Green, M.F.; Grue, B.; Guha, G.; Halicka, D.; Helferich, W.G.; Heneberg, P.; Hentosh, P.; Hirschey, M.D.; Hofseth, L.J.; Holcombe, R.F.; Honoki, K.; Hsu, H.Y.; Huang, G.S.; Jensen, L.D.; Jiang, W.G.; Jones, L.W.; Karpowicz, P.A.; Keith, W.N.; Kerkar, S.P.; Khan, G.N.; Khatami, M.; Ko, Y.H.; Kucuk, O.; Kulathinal, R.J.; Kumar, N.B.; Kwon, B.S.; Le, A.; Lea, M.A.; Lee, H.Y.; Lichtor, T.; Lin, L.T.; Locasale, J.W.; Lokeshwar, B.L.; Longo, V.D.; Lyssiotis, C.A.; MacKenzie, K.L.; Malhotra, M.; Marino, M.; Martinez-Chantar, M.L.; Matheu, A.; Maxwell, C.; McDonnell, E.; Meeker, A.K.; Mehrmohamadi, M.; Mehta, K.; Michelotti, G.A.; Mohammad, R.M.; Mohammed, S.I.; Morre, D.J.; Muralidhar, V.; Muqbil, I.; Murphy, M.P.; Nagaraju, G.P.; Nahta, R.; Niccolai, E.; Nowsheen, S.; Panis, C.; Pantano, F.; Parslow, V.R.; Pawelec, G.; Pedersen, P.L.; Poore, B.; Poudyal, D.; Prakash, S.; Prince, M.; Raffaghello, L.; Rathmell, J.C.; Rathmell, W.K.; Ray, S.K.; Reichrath, J.; Rezazadeh, S.; Ribatti, D.; Ricciardiello, L.; Robey, R.B.; Rodier, F.; Rupasinghe, H.P.V.; Russo, G.L.; Ryan, E.P.; Samadi, A.K.; Sanchez-Garcia, I.; Sanders, A.J.; Santini, D.; Sarkar, M.; Sasada, T.; Saxena, N.K.; Shackelford, R.E.; Shantha Kumara, H.M.C.; Sharma, D.; Shin, D.M.; Sidransky, D.; Siegelin, M.D.; Signori, E.; Singh, N.; Sivanand, S.; Sliva, D.; Smythe, C.; Spagnuolo, C.; Stafforini, D.M.; Stagg, J.; Subbarayan, P.R.; Sundin, T.; Talib, W.H.; Thompson, S.K.; Tran, P.T.; Ungefroren, H.; Vander Heiden, M.G.; Venkateswaran, V.; Vinay, D.S.; Vlachostergios, P.J.; Wang, Z.; Wellen, K.E.; Whelan, R.L.; Yang, E.S.; Yang, H.; Yang, X.; Yaswen, P.; Yedjou, C.; Yin, X.; Zhu, J.; Zollo, M. Designing a broad-spectrum integrative approach for cancer prevention and treatment. Semin. Cancer Biol., 2015, 35(Suppl.), S276-S304.
[http://dx.doi.org/10.1016/j.semcancer.2015.09.007] [PMID: 26590477]

Newman, R.A.; Kondo, Y.; Yokoyama, T.; Dixon, S.; Cartwright, C.; Chan, D.; Johansen, M.; Yang, P. Autophagic cell death of human pancreatic tumor cells mediated by oleandrin, a lipid-soluble cardiac glycoside. Integr. Cancer Ther., 2007, 6(4), 354-364.
[http://dx.doi.org/10.1177/1534735407309623] [PMID: 18048883]

Grabowski, K.; Baringhaus, K.H.; Schneider, G. Scaffold diversity of natural products: inspiration for combinatorial library design. Nat. Prod. Rep., 2008, 25(5), 892-904.
[http://dx.doi.org/10.1039/b715668p] [PMID: 18820757]

Toniatti, C.; Jones, P.; Graham, H.; Pagliara, B.; Draetta, G. Oncology drug discovery: planning a turnaround. Cancer Discov., 2014, 4(4), 397-404.
[http://dx.doi.org/10.1158/2159-8290.CD-13-0452] [PMID: 24706659]

Fang, J.G.; Lu, M.; Chen, Z.H.; Zhu, H.H.; Li, Y.; Yang, L.; Wu, L.M.; Liu, Z.L. Antioxidant effects of resveratrol and its analogues against the free-radical-induced peroxidation of linoleic acid in micelles. Chemistry, 2002, 8(18), 4191-4198.
[http://dx.doi.org/10.1002/1521-3765(20020916)8:18<4191:AID-CHEM4191>3.0.CO;2-S] [PMID: 12298009]

Silvera, D.; Formenti, S.C.; Schneider, R.J. Translational control in cancer. Nat. Rev. Cancer, 2010, 10(4), 254-266.
[http://dx.doi.org/10.1038/nrc2824] [PMID: 20332778]

Bhat, M.; Robichaud, N.; Hulea, L.; Sonenberg, N.; Pelletier, J.; Topisirovic, I. Targeting the translation machinery in cancer. Nat. Rev. Drug Discov., 2015, 14(4), 261-278.
[http://dx.doi.org/10.1038/nrd4505] [PMID: 25743081]

Bordeleau, M.E.; Cencic, R.; Lindqvist, L.; Oberer, M.; Northcote, P.; Wagner, G.; Pelletier, J. RNA-mediated sequestration of the RNA helicase eIF4A by Pateamine A inhibits translation initiation. Chem. Biol., 2006, 13(12), 1287-1295.
[http://dx.doi.org/10.1016/j.chembiol.2006.10.005] [PMID: 17185224]

Murias, M.; Jäger, W.; Handler, N.; Erker, T.; Horvath, Z.; Szekeres, T.; Nohl, H.; Gille, L. Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure-activity relationship. Biochem. Pharmacol., 2005, 69(6), 903-912.
[http://dx.doi.org/10.1016/j.bcp.2004.12.001] [PMID: 15748702]

Letai, A. Functional precision cancer medicine-moving beyond pure genomics. Nat. Med., 2017, 23(9), 1028-1035.
[http://dx.doi.org/10.1038/nm.4389] [PMID: 28886003]

Galsky, M.D.; Dritselis, A.; Kirkpatrick, P.; Oh, W.K. Cabazitaxel. Nat. Rev. Drug Discov., 2010, 9(9), 677-678.

Fostier, K.; De Becker, A.; Schots, R. Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma. OncoTargets Ther., 2012, 5, 237-244.
[PMID: 23055749]

Venditto, V.J.; Simanek, E.E. Cancer therapies utilizing the camptothecins: a review of the in vivo literature. Mol. Pharm., 2010, 7(2), 307-349.
[http://dx.doi.org/10.1021/mp900243b] [PMID: 20108971]

Agrawal, K. Dactinomycin. xPharm Compr. Pharmacol. Ref., 2007, 1-4.,

Côme, M.G.; Skladanowski, A.; Larsen, A.K.; Laurent, G. Dual mechanism of daunorubicin-induced cell death in both sensitive and MDR-resistant HL-60 cells. Br. J. Cancer, 1999, 79(7-8), 1090-1097.
[http://dx.doi.org/10.1038/sj.bjc.6690174] [PMID: 10098741]

Conte, P.F.; Gennari, A.; Landucci, E.; Orlandini, C. Role of epirubicin in advanced breast cancer. Clin. Breast Cancer, 2000, 1(Suppl. 1), S46-S51.
[http://dx.doi.org/10.3816/CBC.2000.s.009] [PMID: 11970749]

Baldwin, E.L.; Osheroff, N. Etoposide, topoisomerase II and cancer. Curr. Med. Chem. Anticancer Agents, 2005, 5(4), 363-372.
[http://dx.doi.org/10.2174/1568011054222364] [PMID: 16101488]

Dybdal-Hargreaves, N.F.; Risinger, A.L.; Mooberry, S.L. Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent. Clin. Cancer Res., 2015, 21(11), 2445-2452.
[http://dx.doi.org/10.1158/1078-0432.CCR-14-3252] [PMID: 25838395]

Lopus, M.; Smiyun, G.; Miller, H.; Oroudjev, E.; Wilson, L.; Jordan, M.A. Mechanism of action of ixabepilone and its interactions with the βIII-tubulin isotype. Cancer Chemother. Pharmacol., 2015, 76(5), 1013-1024.
[http://dx.doi.org/10.1007/s00280-015-2863-z] [PMID: 26416565]

Fujita, K.; Kubota, Y.; Ishida, H.; Sasaki, Y. Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer. World J. Gastroenterol., 2015, 21(43), 12234-12248.
[http://dx.doi.org/10.3748/wjg.v21.i43.12234] [PMID: 26604633]

Zhu, L.; Chen, L. Progress in research on paclitaxel and tumor immunotherapy. Cell. Mol. Biol. Lett., 2019, 24(1), 40.
[http://dx.doi.org/10.1186/s11658-019-0164-y] [PMID: 31223315]

Grant, C.; Rahman, F.; Piekarz, R.; Peer, C.; Frye, R.; Robey, R.W.; Gardner, E.R.; Figg, W.D.; Bates, S.E. Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev. Anticancer Ther., 2010, 10(7), 997-1008.
[http://dx.doi.org/10.1586/era.10.88] [PMID: 20645688]

Agrawal, K. Vinblastine. xPharm Compr. Pharmacol. Ref., 2007, 1-4.,

Moudi, M.; Go, R.; Yien, C.Y.S.; Nazre, M. Vinca alkaloids. Int. J. Prev. Med., 2013, 4(11), 1231-1235.
[PMID: 24404355]

Agrawal, K. Vincristine. xPharm Compr. Pharmacol. Ref., 2007, 1-4.,

D’Incalci, M.; Badri, N.; Galmarini, C.M.; Allavena, P. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment. Br. J. Cancer, 2014, 111(4), 646-650.
[http://dx.doi.org/10.1038/bjc.2014.149] [PMID: 24755886]

Jiang, L.; Zhao, X.; Xu, J.; Li, C.; Yu, Y.; Wang, W.; Zhu, L. The protective effect of dietary phytosterols on cancer risk: a systematic meta-analysis. J. Oncol., 2019, 20197479518
[http://dx.doi.org/10.1155/2019/7479518] [PMID: 31341477]

Zhang, C.; Sheng, J.; Li, G.; Zhao, L.; Wang, Y.; Yang, W.; Yao, X.; Sun, L.; Zhang, Z.; Cui, R. Effects of berberine and its derivatives on cancer: a systems pharmacology review. Front. Pharmacol., 2020, 10, 1461.
[http://dx.doi.org/10.3389/fphar.2019.01461] [PMID: 32009943]

Shen, Y.; Takahashi, M.; Byun, H.M.; Link, A.; Sharma, N.; Balaguer, F.; Leung, H.C.; Boland, C.R.; Goel, A. Boswellic acid induces epigenetic alterations by modulating DNA methylation in colorectal cancer cells. Cancer Biol. Ther., 2012, 13(7), 542-552.
[http://dx.doi.org/10.4161/cbt.19604] [PMID: 22415137]

Rathnavelu, V.; Alitheen, N.B.; Sohila, S.; Kanagesan, S.; Ramesh, R. Potential role of bromelain in clinical and therapeutic applications. Biomed. Rep., 2016, 5(3), 283-288.
[http://dx.doi.org/10.3892/br.2016.720] [PMID: 27602208]

Kashyap, D.; Sharma, A.; Tuli, H.S.; Sak, K.; Mukherjee, T.; Bishayee, A. Molecular targets of celastrol in cancer: recent trends and advancements. Crit. Rev. Oncol. Hematol., 2018, 128, 70-81.
[http://dx.doi.org/10.1016/j.critrevonc.2018.05.019] [PMID: 29958633]

Siemann, D.W.; Chaplin, D.J.; Walicke, P.A. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert Opin. Investig. Drugs, 2009, 18(2), 189-197.
[http://dx.doi.org/10.1517/13543780802691068] [PMID: 19236265]

Shishodia, S.; Chaturvedi, M.M.; Aggarwal, B.B. Role of curcumin in cancer therapy. Curr. Probl. Cancer, 2007, 31(4), 243-305.
[http://dx.doi.org/10.1016/j.currproblcancer.2007.04.001] [PMID: 17645940]

Shehzad, A.; Wahid, F.; Lee, Y.S. Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch. Pharm. (Weinheim), 2010, 343(9), 489-499.
[http://dx.doi.org/10.1002/ardp.200900319] [PMID: 20726007]

Gayathri, R.; Gunadharini, D.N.; Arunkumar, A.; Senthilkumar, K.; Krishnamoorthy, G.; Banudevi, S.; Vignesh, R.C.; Arunakaran, J. Effects of diallyl disulfide (DADS) on expression of apoptosis associated proteins in androgen independent human prostate cancer cells (PC-3). Mol. Cell. Biochem., 2009, 320(1-2), 197-203.
[http://dx.doi.org/10.1007/s11010-008-9903-5] [PMID: 18759062]

Gupta, K.; Gupta, S. The chemopreventive and chemotherapeutic potentials of tea polyphenols. Curr. Pharm. Biotechnol., 2011, 13(1), 191-199.

Kim, S-H.; Kim, C-W.; Jeon, S-Y.; Go, R-E.; Hwang, K-A.; Choi, K-C. Chemopreventive and chemotherapeutic effects of genistein, a soy isoflavone, upon cancer development and progression in preclinical animal models. Lab. Anim. Res., 2014, 30(4), 143-150.
[http://dx.doi.org/10.5625/lar.2014.30.4.143] [PMID: 25628724]

Bordeleau, M.E.; Mori, A.; Oberer, M.; Lindqvist, L.; Chard, L.S.; Higa, T.; Belsham, G.J.; Wagner, G.; Tanaka, J.; Pelletier, J. Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A. Nat. Chem. Biol., 2006, 2(4), 213-220.
[http://dx.doi.org/10.1038/nchembio776] [PMID: 16532013]

Benhadji, K.A.; Serova, M.; Ghoul, A.; Cvitkovic, E.; Le Tourneau, C.; Ogbourne, S.M.; Lokiec, F.; Calvo, F.; Hammel, P.; Faivre, S.; Raymond, E. Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells. Br. J. Cancer, 2008, 99(11), 1808-1815.
[http://dx.doi.org/10.1038/sj.bjc.6604642] [PMID: 19034280]

Bodduluru, L.N.; Kasala, E.R.; Thota, N.; Barua, C.C.; Sistla, R. Chemopreventive and therapeutic effects of nimbolide in cancer: the underlying mechanisms. Toxicol. In Vitro, 2014, 28(5), 1026-1035.
[http://dx.doi.org/10.1016/j.tiv.2014.04.011] [PMID: 24759803]

Samanta, S.K.; Bhattacharya, K.; Mandal, C.; Pal, B.C. Identification and quantification of the active component quercetin 3-O-rutinoside from Barringtonia racemosa, targets mitochondrial apoptotic pathway in acute lymphoblastic leukemia. J. Asian Nat. Prod. Res., 2010, 12(8), 639-648.
[http://dx.doi.org/10.1080/10286020.2010.489040] [PMID: 20706898]

Athar, M.; Back, J.H.; Tang, X.; Kim, K.H.; Kopelovich, L.; Bickers, D.R.; Kim, A.L. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol. Appl. Pharmacol., 2007, 224(3), 274-283.
[http://dx.doi.org/10.1016/j.taap.2006.12.025] [PMID: 17306316]

Hsu, J.H.M.; Chang, P.M.H.; Cheng, T.S.; Kuo, Y.L.; Wu, A.T.H.; Tran, T.H.; Yang, Y.H.; Chen, J.M.; Tsai, Y.C.; Chu, Y.S.; Huang, T.H.; Huang, C.F.; Lai, J.M. Identification of withaferin a as a potential candidate for anti-cancer therapy in non-small cell lung cancer. Cancers (Basel), 2019, 11(7), 1003.
[http://dx.doi.org/10.3390/cancers11071003] [PMID: 31319622]

van’t Veer, L.J.; Bernards, R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature, 2008, 452(7187), 564-570.
[http://dx.doi.org/10.1038/nature06915] [PMID: 18385730]

Kelloff, G.J.; Sigman, C.C. Cancer biomarkers: selecting the right drug for the right patient. Nat. Rev. Drug Discov., 2012, 11(3), 201-214.
[http://dx.doi.org/10.1038/nrd3651] [PMID: 22322254]

Cimino, G.D.; Pan, C.X.; Henderson, P.T. Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer. Bioanalysis, 2013, 5(3), 369-391.
[http://dx.doi.org/10.4155/bio.12.325] [PMID: 23394702]

Farmer, P.B. Metabolism and reactions of alkylating agents. Pharmacol. Ther., 1987, 35(3), 301-358.
[http://dx.doi.org/10.1016/0163-7258(87)90099-4] [PMID: 3324117]

Povirk, L.F.; Shuker, D.E. DNA damage and mutagenesis induced by nitrogen mustards. Mutat. Res., 1994, 318(3), 205-226.
[http://dx.doi.org/10.1016/0165-1110(94)90015-9] [PMID: 7527485]

Harris, C.C. Chemical and physical carcinogenesis: advances and perspectives for the 1990s. Cancer Res., 1991, 51(18)(Suppl.), 5023s-5044s.
[PMID: 1884379]

Zoppoli, G.; Regairaz, M.; Leo, E.; Reinhold, W.C.; Varma, S.; Ballestrero, A.; Doroshow, J.H.; Pommier, Y. Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proc. Natl. Acad. Sci. USA, 2012, 109(37), 15030-15035.
[http://dx.doi.org/10.1073/pnas.1205943109] [PMID: 22927417]

Sousa, F.G.; Matuo, R.; Tang, S.W.; Rajapakse, V.N.; Luna, A.; Sander, C.; Varma, S.; Simon, P.H.; Doroshow, J.H.; Reinhold, W.C.; Pommier, Y. Alterations of DNA repair genes in the NCI-60 cell lines and their predictive value for anticancer drug activity. DNA Repair (Amst.), 2015, 28, 107-115.
[http://dx.doi.org/10.1016/j.dnarep.2015.01.011] [PMID: 25758781]

Rees, M.G.; Seashore-Ludlow, B.; Cheah, J.H.; Adams, D.J.; Price, E.V.; Gill, S.; Javaid, S.; Coletti, M.E.; Jones, V.L.; Bodycombe, N.E.; Soule, C.K.; Alexander, B.; Li, A.; Montgomery, P.; Kotz, J.D.; Hon, C.S.; Munoz, B.; Liefeld, T.; Dančík, V.; Haber, D.A.; Clish, C.B.; Bittker, J.A.; Palmer, M.; Wagner, B.K.; Clemons, P.A.; Shamji, A.F.; Schreiber, S.L. Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nat. Chem. Biol., 2016, 12(2), 109-116.
[http://dx.doi.org/10.1038/nchembio.1986] [PMID: 26656090]

Jarvis, I.W.H.; Meczes, E.L.; Thomas, H.D.; Edmondson, R.J.; Veal, G.J.; Boddy, A.V.; Ottley, C.J.; Pearson, D.G.; Tilby, M.J. Therapy-induced carboplatin-DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tissues. Biochem. Pharmacol., 2012, 83(1), 69-77.
[http://dx.doi.org/10.1016/j.bcp.2011.10.005] [PMID: 22015635]

Bartelink, H.; Begg, A.; Martin, J.C.; van Dijk, M.; van ’t Veer, L.; van der Vaart, P.; Verheij, M. Towards prediction and modulation of treatment response. Radiother. Oncol., 1999, 50(1), 1-11.
[http://dx.doi.org/10.1016/S0167-8140(99)00009-2] [PMID: 10225551]

Konner, J.A.; Grabon, D.; Pezzulli, S.; Iasonos, A.; Sabbatini, P.; Hensley, M. A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel, IP cisplatin, and IV bevacizumab as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer. J. Clin. Oncol., 2009, 27(15_suppl), 5539-5539.,

Reed, E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat. Rev., 1998, 24(5), 331-344.
[http://dx.doi.org/10.1016/S0305-7372(98)90056-1] [PMID: 9861196]

Gewirtz, D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol., 1999, 57(7), 727-741.
[http://dx.doi.org/10.1016/S0006-2952(98)00307-4] [PMID: 10075079]

Tewey, K.M.; Rowe, T.C.; Yang, L.; Halligan, B.D.; Liu, L.F. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science, 1984, 226(4673), 466-468.
[http://dx.doi.org/10.1126/science.6093249] [PMID: 6093249]

Verma, M. Viral genes and methylation. Ann. N. Y. Acad. Sci., 2003, 983(1), 170-180.
[http://dx.doi.org/10.1111/j.1749-6632.2003.tb05972.x] [PMID: 12724222]

Ellis, L.; Atadja, P.W.; Johnstone, R.W. Epigenetics in cancer: targeting chromatin modifications. Mol. Cancer Ther., 2009, 8(6), 1409-1420.
[http://dx.doi.org/10.1158/1535-7163.MCT-08-0860] [PMID: 19509247]

Verma, M.; Srivastava, S. Epigenetics in cancer: implications for early detection and prevention. Lancet Oncol., 2002, 3(12), 755-763.
[http://dx.doi.org/10.1016/S1470-2045(02)00932-4] [PMID: 12473517]

Zhang, Y.; Xu, W. Isoform-selective histone deacetylase inhibitors: the trend and promise of disease treatment. Epigenomics, 2015, 7(1), 5-7.
[http://dx.doi.org/10.2217/epi.14.62] [PMID: 25687460]

Ahrens, T.D.; Timme, S.; Ostendorp, J.; Bogatyreva, L.; Hoeppner, J.; Hopt, U.T.; Hauschke, D.; Werner, M.; Lassmann, S. Response of esophageal cancer cells to epigenetic inhibitors is mediated via altered thioredoxin activity. Lab. Invest., 2016, 96(3), 307-316.
[http://dx.doi.org/10.1038/labinvest.2015.148] [PMID: 26692290]

Park, H.; Garrido-Laguna, I.; Naing, A.; Fu, S.; Falchook, G.S.; Piha-Paul, S.A.; Wheler, J.J.; Hong, D.S.; Tsimberidou, A.M.; Subbiah, V.; Zinner, R.G.; Kaseb, A.O.; Patel, S.; Fanale, M.A.; Velez-Bravo, V.M.; Meric-Bernstam, F.; Kurzrock, R.; Janku, F. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget, 2016, 7(41), 67521-67531.
[http://dx.doi.org/10.18632/oncotarget.11750] [PMID: 27589687]

Shi, X.; Li, M.; Cui, M.; Niu, C.; Xu, J.; Zhou, L.; Li, W.; Gao, Y.; Kong, W.; Cui, J.; Hu, J.; Jin, H. Epigenetic suppression of the antitumor cytotoxicity of NK cells by histone deacetylase inhibitor valproic acid. Am. J. Cancer Res., 2016, 6(3), 600-614.
[PMID: 27152238]

Chiappinelli, K.B.; Strissel, P.L.; Desrichard, A.; Li, H.; Henke, C.; Akman, B.; Hein, A.; Rote, N.S.; Cope, L.M.; Snyder, A.; Makarov, V.; Budhu, S.; Slamon, D.J.; Wolchok, J.D.; Pardoll, D.M.; Beckmann, M.W.; Zahnow, C.A.; Merghoub, T.; Chan, T.A.; Baylin, S.B.; Strick, R. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell, 2015, 162(5), 974-986.
[http://dx.doi.org/10.1016/j.cell.2015.07.011] [PMID: 26317466]

Tanaka, M.; Roberts, J.M.; Qi, J.; Bradner, J.E. Inhibitors of emerging epigenetic targets for cancer therapy: a patent review (2010-2014). Pharm. Pat. Anal., 2015, 4(4), 261-284.
[http://dx.doi.org/10.4155/ppa.15.16] [PMID: 26174566]

Mazur, P.K.; Herner, A.; Mello, S.S.; Wirth, M.; Hausmann, S.; Sánchez-Rivera, F.J.; Lofgren, S.M.; Kuschma, T.; Hahn, S.A.; Vangala, D.; Trajkovic-Arsic, M.; Gupta, A.; Heid, I.; Noël, P.B.; Braren, R.; Erkan, M.; Kleeff, J.; Sipos, B.; Sayles, L.C.; Heikenwalder, M.; Heßmann, E.; Ellenrieder, V.; Esposito, I.; Jacks, T.; Bradner, J.E.; Khatri, P.; Sweet-Cordero, E.A.; Attardi, L.D.; Schmid, R.M.; Schneider, G.; Sage, J.; Siveke, J.T. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nat. Med., 2015, 21(10), 1163-1171.
[http://dx.doi.org/10.1038/nm.3952] [PMID: 26390243]

Borodovsky, A.; Salmasi, V.; Turcan, S.; Fabius, A.W.M.; Baia, G.S.; Eberhart, C.G.; Weingart, J.D.; Gallia, G.L.; Baylin, S.B.; Chan, T.A.; Riggins, G.J. 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget, 2013, 4(10), 1737-1747.
[http://dx.doi.org/10.18632/oncotarget.1408] [PMID: 24077805]

Turcan, S.; Rohle, D.; Goenka, A.; Walsh, L.A.; Fang, F.; Yilmaz, E.; Campos, C.; Fabius, A.W.; Lu, C.; Ward, P.S.; Thompson, C.B.; Kaufman, A.; Guryanova, O.; Levine, R.; Heguy, A.; Viale, A.; Morris, L.G.; Huse, J.T.; Mellinghoff, I.K.; Chan, T.A. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature, 2012, 483(7390), 479-483.
[http://dx.doi.org/10.1038/nature10866] [PMID: 22343889]

Weisenberger, D.J.; Siegmund, K.D.; Campan, M.; Young, J.; Long, T.I.; Faasse, M.A.; Kang, G.H.; Widschwendter, M.; Weener, D.; Buchanan, D.; Koh, H.; Simms, L.; Barker, M.; Leggett, B.; Levine, J.; Kim, M.; French, A.J.; Thibodeau, S.N.; Jass, J.; Haile, R.; Laird, P.W. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet., 2006, 38(7), 787-793.
[http://dx.doi.org/10.1038/ng1834] [PMID: 16804544]

Azad, N.; Zahnow, C.A.; Rudin, C.M.; Baylin, S.B. The future of epigenetic therapy in solid tumours-lessons from the past. Nat. Rev. Clin. Oncol., 2013, 10(5), 256-266.
[http://dx.doi.org/10.1038/nrclinonc.2013.42] [PMID: 23546521]

Yang, A.S.; Doshi, K.D.; Choi, S.W.; Mason, J.B.; Mannari, R.K.; Gharybian, V.; Luna, R.; Rashid, A.; Shen, L.; Estecio, M.R.; Kantarjian, H.M.; Garcia-Manero, G.; Issa, J.P. DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia. Cancer Res., 2006, 66(10), 5495-5503.
[http://dx.doi.org/10.1158/0008-5472.CAN-05-2385] [PMID: 16707479]

Wang, Y.; Sun, S.; Zhang, Z.; Shi, D. Nanomaterials for cancer precision medicine. Adv. Mater., 2018, 30(17)e1705660
[http://dx.doi.org/10.1002/adma.201705660] [PMID: 29504159]

Calabretta, M.M.; Zangheri, M.; Lopreside, A.; Marchegiani, E.; Montali, L.; Simoni, P.; Roda, A. Precision medicine, bioanalytics and nanomaterials: toward a new generation of personalized portable diagnostics. Analyst (Lond.), 2020, 145(8), 2841-2853.
[http://dx.doi.org/10.1039/C9AN02041A] [PMID: 32196042]

Joo, J.I.; Choi, M.; Jang, S.H.; Choi, S.; Park, S.M.; Shin, D.; Cho, K.H. Realizing cancer precision medicine by integrating systems biology and nanomaterial engineering. Adv. Mater., 2020, 32(35)e1906783
[http://dx.doi.org/10.1002/adma.201906783] [PMID: 32253807]

Keles, E.; Song, Y.; Du, D.; Dong, W.J.; Lin, Y. Recent progress in nanomaterials for gene delivery applications. Biomater. Sci., 2016, 4(9), 1291-1309.
[http://dx.doi.org/10.1039/C6BM00441E] [PMID: 27480033]

Tuantranont, A. Applications of Nanomaterials in Sensors and Diagnostics; Springer: Amsterdam, 2013.
[http://dx.doi.org/10.1007/978-3-642-36025-1]

Lee, C.S.; Bishop, E.S.; Zhang, R.; Yu, X.; Farina, E.M.; Yan, S.; Zhao, C.; Zheng, Z.; Shu, Y.; Wu, X.; Lei, J.; Li, Y.; Zhang, W.; Yang, C.; Wu, K.; Wu, Y.; Ho, S.; Athiviraham, A.; Lee, M.J.; Wolf, J.M.; Reid, R.R.; He, T.C. Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine. Genes Dis., 2017, 4(2), 43-63.
[http://dx.doi.org/10.1016/j.gendis.2017.04.001] [PMID: 28944281]

Duffy, D.J. Problems, challenges and promises: perspectives on precision medicine. Brief. Bioinform., 2016, 17(3), 494-504.
[http://dx.doi.org/10.1093/bib/bbv060] [PMID: 26249224]

Personalized Medicine: Trends and prospects for the new science of genetic testing and molecular diagnostics. Work Paper, 2012, 7.

Karapetis, C.S.; Khambata-Ford, S.; Jonker, D.J.; O’Callaghan, C.J.; Tu, D.; Tebbutt, N.C.; Simes, R.J.; Chalchal, H.; Shapiro, J.D.; Robitaille, S.; Price, T.J.; Shepherd, L.; Au, H.J.; Langer, C.; Moore, M.J.; Zalcberg, J.R. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med., 2008, 359(17), 1757-1765.
[http://dx.doi.org/10.1056/NEJMoa0804385] [PMID: 18946061]

De Roock, W.; Claes, B.; Bernasconi, D.; De Schutter, J.; Biesmans, B.; Fountzilas, G.; Kalogeras, K.T.; Kotoula, V.; Papamichael, D.; Laurent-Puig, P.; Penault-Llorca, F.; Rougier, P.; Vincenzi, B.; Santini, D.; Tonini, G.; Cappuzzo, F.; Frattini, M.; Molinari, F.; Saletti, P.; De Dosso, S.; Martini, M.; Bardelli, A.; Siena, S.; Sartore-Bianchi, A.; Tabernero, J.; Macarulla, T.; Di Fiore, F.; Gangloff, A.O.; Ciardiello, F.; Pfeiffer, P.; Qvortrup, C.; Hansen, T.P.; Van Cutsem, E.; Piessevaux, H.; Lambrechts, D.; Delorenzi, M.; Tejpar, S. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol., 2010, 11(8), 753-762.
[http://dx.doi.org/10.1016/S1470-2045(10)70130-3] [PMID: 20619739]

Seymour, C.W.; Gomez, H.; Chang, C.H.; Clermont, G.; Kellum, J.A.; Kennedy, J.; Yende, S.; Angus, D.C. Precision medicine for all? Challenges and opportunities for a precision medicine approach to critical illness. Crit. Care, 2017, 21(1), 257.
[http://dx.doi.org/10.1186/s13054-017-1836-5] [PMID: 29047353]

Wolkenhauer, O.; Auffray, C.; Brass, O.; Clairambault, J.; Deutsch, A.; Drasdo, D.; Gervasio, F.; Preziosi, L.; Maini, P.; Marciniak-Czochra, A.; Kossow, C.; Kuepfer, L.; Rateitschak, K.; Ramis-Conde, I.; Ribba, B.; Schuppert, A.; Smallwood, R.; Stamatakos, G.; Winter, F.; Byrne, H. Enabling multiscale modeling in systems medicine. Genome Med., 2014, 6(3), 21.
[http://dx.doi.org/10.1186/gm538] [PMID: 25031615]

Auton, A.; Brooks, L.D.; Durbin, R.M.; Garrison, E.P.; Kang, H.M.; Korbel, J.O.; Marchini, J.L.; McCarthy, S.; McVean, G.A.; Abecasis, G.R. A global reference for human genetic variation. Nature, 2015, 526(7571), 68-74.
[http://dx.doi.org/10.1038/nature15393] [PMID: 26432245]

Henderson, T.O.; Bhatia, S.; Pinto, N.; London, W.B.; McGrady, P.; Crotty, C.; Sun, C.L.; Cohn, S.L. Racial and ethnic disparities in risk and survival in children with neuroblastoma: a Children’s Oncology Group study. J. Clin. Oncol., 2011, 29(1), 76-82.
[http://dx.doi.org/10.1200/JCO.2010.29.6103] [PMID: 21098321]

Bierman, A.S.; Tinetti, M.E. Precision medicine to precision care: managing multimorbidity. Lancet, 2016, 388(10061), 2721-2723.
[http://dx.doi.org/10.1016/S0140-6736(16)32232-2] [PMID: 27924764]

Tinetti, M.E.; Bogardus, S.T., Jr; Agostini, J.V. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N. Engl. J. Med., 2004, 351(27), 2870-2874.
[http://dx.doi.org/10.1056/NEJMsb042458] [PMID: 15625341]

Gavan, S.P.; Thompson, A.J.; Payne, K. The economic case for precision medicine. Expert Rev. Precis. Med. Drug Dev., 2018, 3(1), 1-9.
[http://dx.doi.org/10.1080/23808993.2018.1421858] [PMID: 29682615]

Towse, A.; Garrison, L. Value assessment in precision cancer medicine. J. Cancer Policy, 2017, 11, 48-53.
[http://dx.doi.org/10.1016/j.jcpo.2016.09.003]

Shin, S.H.; Bode, A.M.; Dong, Z. Addressing the challenges of applying precision oncology. NPJ Precis. Oncol., 2017, 1(1), 28.
[http://dx.doi.org/10.1038/s41698-017-0032-z] [PMID: 29872710]

Mullard, A. NCI-MATCH trial pushes cancer umbrella trial paradigm. Nat. Rev. Drug Discov., 2015, 14(8), 513-515.
[http://dx.doi.org/10.1038/nrd4694] [PMID: 26228747]

Dzau, V.J.; Ginsburg, G.S. Realizing the full potential of precision medicine in health and health care. JAMA, 2016, 316(16), 1659-1660.
[http://dx.doi.org/10.1001/jama.2016.14117] [PMID: 27669484]